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ABSTRACT 
 
 
In these studies, an implant device was developed to detect vaccination-induced, 
cell-mediated immunity in the subcutaneous tissue of calves. The long-term, future aim 
of these combined studies is to use the implant device to efficiently screen novel 
Mycobacterium avium subsp. paratuberculosis (MAP) vaccine candidates. This in vivo 
screening test would rapidly and inexpensively provide knowledge of a vaccine’s 
efficacy in the host species; vaccine candidates exhibiting evidence of efficacy could then 
be selected for more extensive vaccine challenge studies. A better understanding of in 
vivo cell-mediated immunity in response to MAP immunization is essential for the 
development of a novel vaccine screening test. In all of the studies presented, Mycopar® 
vaccinated bull calves were compared to unvaccinated, control calves. Our first specific 
aim was based on a proof-of-concept study that focused on the development of a platform 
for in vivo detection of cell-mediated immunity in cattle. The results of the study showed 
that MAP-specific in vivo measurements can be achieved with the use of our designed 
implant device. Histological analysis revealed a lack of cellular infiltrate in naïve calves 
as well as the vaccinated calf not challenged with the MAP antigen, purified protein 
derivative-johnin (PPD-J). This demonstrated antigen-dependent immune cell recruitment 
into the collagen of the implant and illustrated the collagen’s capacity for cellular 
migration. IFNwas only detected in the antigen-containing implants that were placed in 
vaccinated calves. IL-10 did not exhibit antigen or vaccine-dependent trends.  In a 
longitudinal analysis, the implants were measured at 0, 2, 4, 6, and 8 weeks post- 
vaccination. IFNlevels in the MAP antigen-containing implants placed in vaccinated 
calves were significantly higher than the implants retrieved from naïve cattle at weeks 4 
 
 
vii 
 
 
 
 
and 6 post-vaccination. These responses paralleled the responses observed in MAP- 
stimulated peripheral blood leukocytes (PBL) from vaccinated calves. Significant  
differences in IL-10 levels between the implants within vaccinated and naïve calves were 
not observed. The intradermal caudal fold test (CFT) demonstrated false-positive rates 
when one of our calves reacted to PPD-J prior to vaccination. This indicated that our 
implant device was capable of identifying each of the 3 vaccinated calves, suggesting an 
increased specificity over the intradermal CFT using PPD-J. Using live MAP bacteria, 
we explored the device’s potential as a bacterial killing assay; collagen and bacteria- 
containing implant devices were placed in the subcutaneous tissues of calves divided into 
two groups, naïve and vaccinated calves, at 14 and 20 days post-vaccination. After 5 
days, implants were retrieved from the subcutaneous tissues and collagen was processed 
for evaluation of IFNcytokine levels and flow cytometric analysis of bacterial viability. 
Three weeks post-vaccination, bacteria was removed from the 5-day implanted collagen, 
and flow cytometric analysis of the bacteria demonstrated a significantly greater 
percentage of propidium iodide (PI) stained-MAP in the vaccinated calves compared to 
the naïve calves. This finding indicated an enhancement of bacterial killing within 
collagen implants placed in vaccinated calves. Collagen from vaccinated calves at the 
three week post-vaccination time point also demonstrated a significantly higher 
production of IFN than collagen from naïve calves. The work of this dissertation 
provides supporting evidence that a subcutaneous bacterial challenge model could prove 
to be an efficient and cost-effective method for screening novel vaccine candidates in a 
natural host model.
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CHAPTER 1. GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
Dissertation Organization 
 
This dissertation is organized in the journal format in which each chapter is an 
independent manuscript. The chapters follow the submission guidelines for the specific 
journals in which they will be submitted. Chapter 1 is comprised of an overview and 
literature review and is followed by three individual manuscripts (Chapters 2-4). Chapter 5 
contains general conclusions and future directions with references cited at the end of each 
individual chapter. 
 
 
Disease Overview 
 
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent of 
paratuberculosis in ruminants around the world. MAP infection, also known as Johne’s 
disease, is characterized by chronic granulomatous enteritis resulting in a general wasting 
condition noted by the clinical signs of diarrhea, weight loss, and loss of milk production [1- 
3]. The greatest risk of infection occurs during the neonatal period, and vertical transmission 
from cow to calf is considered the most common route of infection; however, horizontal 
transmission from calf to calf or newly acquired cow is also observed [1, 4]. It is well 
established that calves are most susceptible to MAP infection the first few days to months of 
life [1, 4, 5]. Age-related MAP resistance has been demonstrated and by one year of age, 
cattle are considered low risk for infection [4]. The majority of calves that are exposed to 
MAP do not develop chronic wasting disease. In fact, only 10-15% of exposed calves will 
progress with symptoms of clinical disease after a prolonged incubation period that is known 
to last from 2-10 years [1, 4]. During this phase of infection, known as Stage I, clinical signs 
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and bacterial shedding do not occur; therefore, detection of MAP in this stage of disease is 
particularly difficult. Stage I animals contribute to the spread of infection in a herd by 
progressing to the advanced disease stages (Stages II-IV) that are known to shed MAP into 
the environment and eventually contribute to significant economic losses [1]. The annual 
monetary loss due to low milk production and early cull rates is estimated between $200-500 
million with at least 68% of dairy herds in the United States containing MAP infected cattle 
[1, 6]. Treatment is not typically an option due to the high cost of antimycobacterial 
therapeutic agents combined with the high doses required for long treatment periods. Current 
methods of control include reducing MAP infection within a herd by testing and removing 
infected cows, prevention of new infections, vaccination, and genetic selection [1, 7]. 
Unfortunately, current diagnostics are infrequently able to detect subclinical stages of 
infection (Stage I, II). Due to difficulty in identifying MAP-infected animals, vaccination is 
increasingly looked to for control and elimination of MAP from cattle herds. The currently 
available vaccines do not fully prevent infection and may interfere with diagnostic testing for 
Mycobacterium bovis, although they do decrease fecal shedding [1, 7]. Development of new 
vaccines against paratuberculosis is an area of active research; however, an obstacle 
hindering the development of new, more effective vaccines is the difficulty in testing vaccine 
candidates. This is due to the long incubation period following infection that causes bovine 
vaccine challenge studies to be time-consuming and expensive. Furthermore, alternative 
models using rodents and cell culture systems do not accurately predict the bovine immune 
response to vaccines [3, 8].  The projects included in this dissertation are directed toward 
better understanding the early, post-vaccination, cell-mediated immune response in cattle to 
facilitate the development of an improved model for challenging MAP vaccine candidates. 
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Specific Project Aims 
 
The objective of the research contained in this dissertation was directed at achieving a 
greater understanding of the early, in vivo, cell-mediated immune response in cattle 
vaccinated against MAP. Detection of cell-mediated immune responses is a central 
component of testing new vaccines against mycobacterial infections, and the long-term goal 
of these studies is to develop a novel screening tool to evaluate the efficacy of MAP vaccine 
candidates. This in vivo screening test would provide knowledge of vaccine efficacy for a 
target species in an inexpensive and short time frame. Vaccine candidates that show 
evidence of efficacy could be moved to more thorough vaccine challenge studies in calves. 
To achieve this goal, we first developed a novel subcutaneous implant device to evaluate the 
subcutaneous immune responses occurring post-vaccination (Chapter 2). Our hypothesis for 
these studies was that the implant device will detect vaccination-induced cell-mediated 
immunity in vaccinated calves as well as serve as a mechanism to measure MAP viability 
post-vaccination. To test our hypothesis, our first study was a longitudinal investigation 
evaluating the device’s success at identifying vaccinated calves from naïve calves (Chapter 
3). Our final aim was to use the device to implant live MAP subcutaneously and detect 
immune responses to live bacteria and assess bacterial viability (Chapter 4). 
 
 
Literature Review 
 
Adaptive immunology of MAP infection: Introduction 
 
It is well understood that the adaptive immune system plays an important role in the early 
course of MAP infection in cattle. It has been shown that the early stage of infection begins 
with a cell-mediated immune response that later switches to an ineffective humoral response 
as the disease progresses past the subclinical phase [9-12]. This cell-mediated immune 
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response begins when orally ingested bacteria travel to the ileum where they are 
phagocytized by the microfold (M) cells within the Peyer’s patches and transported to the 
submucosa. Here, bacteria are ingested by epithelial macrophages and dendritic cells [4, 13, 
14]. Following the uptake of bacteria in the ileal macrophages, an appropriate T helper 1 
(Th1) immune response ensues and is primarily directed by type 1 CD4+ T cells [9, 10]. An 
effective Th1 response is necessary for controlling disease and is characterized by the release 
of pro-inflammatory cytokines, such as IFN[12, 15]. The transition from the subclinical to 
clinical stage of disease occurs with deterioration of the Th1 response and development of a 
T helper 2 (Th2) immune response and is characterized by production of Th2 cytokines, such 
as IL-10 [16]. Secretion of Th2 cytokines facilitates a humoral immune response by 
stimulating B lymphocyte proliferation while inhibiting Th1 cytokines [17-19]. This review 
will highlight the Th1/Th2 paradigm, delayed-type hypersensitivity (DTH) intradermal skin 
test, and cytokines associated with the adaptive immune response observed in MAP 
infection. 
 
 
Th1 to Th2 paradigm 
 
The host immune response to MAP infection is complex, with cell-mediated immune 
responses seen during the early, subclinical stage of infection, and humoral responses 
observed during the late, clinical stage of infection. Investigations in cattle and mice have 
demonstrated the ability of IFNand the Th1 response to contain infection and halt disease 
progression [16, 20]. Other studies have shown early stage lesions to have high levels of 
IFNassociated with a Th1 immune response [16]. It is plausible that the Th1/IFNresponse is 
contributing to the protective response typically observed in the subclinical stage; evidence 
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to support this includes IFN’s ability to initiate killing of MAP within macrophages [21]. 
Begg et al. used naturally infected sheep to show a correlation between lesion severity and 
Th1/Th2 response. In the study, MAP-infected sheep with less extensive lesions had stronger 
Th1-type cytokines present [9].  A second sheep investigation looking at antigen-specific 
IFNlevels demonstrated an association between low IFNlevels and an increase in the 
severity of ovine paratuberculosis [22]. In vitro bovine monocyte studies have shown a 
decrease in IFNsignaling associated with MAP-infected monocytes [4, 22]. Numerous 
murine models have been used to study the Th1 response in mycobacterial infections. Orme 
et al. demonstrated that mice injected with M. tuberculosis exhibited a high level of IFNfor 
30 days post-infection. After thirty days post-infection of mice, IFNlevels dropped and an 
increase in IL-4 levels were observed indicating the switch from a Th1 to a Th2 response, 
respectively [23]. A second murine study used IFNknock-out mice to demonstrate the 
importance of IFNsignaling and the Th1 response during early infection. This study showed 
disseminated tuberculosis in mice with a knock-out of the IFNgene [24]. These studies 
described in cattle and mice have demonstrated that MAP infection induces a Th1 protective 
response capable of containing infection and halting disease progression. 
The transition from the subclinical to clinical disease state is associated with the 
differentiation of naïve CD4+ T-cells to a Th2 immune response. The production of Th2 
cytokines support a humoral immune response by stimulating the proliferation of B 
lymphocytes and inhibiting Th1 cytokines [25]. Various studies in ruminants and humans 
have validated the correlation between mycobacterial disease progression and a Th2 immune 
response. As previously stated, Begg et al. was able to show that MAP-infected sheep with a 
predominance of Th1-type cytokines had less extensive intestinal lesions. In contrast, sheep 
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with late stage disease and more extensive intestinal lesions had higher levels of MAP- 
specific IgG antibodies indicating the predominance of a Th2 immune response [9]. A 
different study in humans showed the Th2 response and its association with disease 
progression. Seah et al. measured IL-4 mRNA levels in M. tuberculosis–infected humans; 
increased levels of IL-4 mRNA were observed with patients in advanced diseased states [26]. 
The results of these sheep and human studies support a switch from a Th1 to a Th2 immune 
response that is correlated with progression of mycobacterial disease. 
Presently, the cause of the Th1/Th2 shift is still unknown. However, numerous theories 
for the Th1/Th2 immune paradigm switch have been proposed and include periparturient 
hormonal fluctuations, bacterial load, T cell exhaustion, and regulatory T cells (Treg) 
limiting Th1-type responses.  In some recent long-term studies using experimentally infected 
sheep models, the traditional Th1 to Th2 transition has not been observed. In fact, these 
studies show that early in the course of infection both Th1 and Th2 responses are present [27, 
28]. For instance, Waters et al. used experimentally infected calves to longitudinally evaluate 
IFNlevels and humoral antibody levels by absorbed ELISA. This study showed MAP- 
specific antibody detection in the early stage of experimental MAP infection before clinical 
disease is observed [28]. A separate investigation in sheep by Begg et al. concluded that the 
Th1/Th2 immune responses in an ovine model are more complex than previous 
investigations indicated.  Begg et al. used sheep to demonstrate both antibody and cell- 
mediated immunity as key players in early MAP infection. The results of this study showed 
50% of sheep have a combined IFNand antibody response and 39% of sheep demonstrated a 
switch from IFNto predominately antibody production. The sheep with more extensive 
disease were found to have a reduced Th1 response characterized by a decrease in functional 
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ability to produce IFN[9]. Mathematical modeling of MHC Class II-mediated immune responses 
has been demonstrated in tissues [85]. In a new study by Magombedze et al., the previous data 
by Begg et al. was reexamined via a mathematical model. In this study, 39% of sheep 
exhibited a classical Th1 to Th2 switch, 50% exhibited a combined Th1 and Th2 response, 
and 11% exhibited only a Th1 response [29]. There is still ambiguity in the literature 
regarding the differences in Th1/Th2 responses among infected sheep. This novel 
mathematical model is used to evaluate the dynamics of MAP-specific Th1 and Th2 
responses. The mathematical model was based on known properties of mycobacterial 
infections, experimental knowledge, and a theoretical understanding of Th1 and Th2 cells 
compared to naïve T cells (Th0). The results of this study suggested that when a Th1 to Th2 
transition occurs it may be initiated by the accumulation of long-living extracellular bacteria, 
which contradicts previous theories in which the Th1 to Th2 switch was believed to come 
first and induce a proliferation of the bacterial population [29]. This mathematical model, 
along with the recent longitudinal sheep studies described, has shifted the discussion of cell-
mediated immunity and the Th1/Th2 paradigm in mycobacterial disease toward a potential 
protective role of the humoral response in early infection. 
 
 
Delayed-type hypersensitivity and johnin intradermal testing 
 
The cell-mediated immune (CMI) response in cattle is considered the initial host response 
against mycobacterial infections [9, 29]. Therefore, CMI testing may be a useful tool for 
early detection of infection and as a screening test for vaccine efficacy trials.  Currently, 
evaluation for the presence of CMI in humans and animals often includes delayed-type 
hypersensitivity (DTH) intradermal testing. French physician Charles Mantoux originally 
developed the currently used Mantoux tuberculin skin test (TST) in 1912 from the work of 
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previous scientists [30]. The DTH response, also known as a Type IV hypersensitivity 
response, appears hours to days after antigen exposure and represents an immune reaction 
mediated by T lymphocytes. The pathogenesis of the DTH intradermal skin test begins with 
the phagocytosis and processing of antigen by antigen-presenting cells (APC) such as 
dendritic cells and macrophages. The inflammatory reaction that ensues is caused by Th1 
cells that infiltrate the site of antigen exposure and recognize complexes of peptide: MHC 
class II molecules on APCs. This peptide recognition between a previously primed Th1 cell 
and an APC is followed by secretion of pro-inflammatory cytokines such as IFN. The pro- 
inflammatory cytokines then act on local vascular endothelium to stimulate vessel 
permeability allowing plasma and an inflammatory cell infiltrate to enter the antigen 
exposure site. The mediators released by Th1 cells in the DTH response include chemokines 
and cytokines that facilitate recruitment of macrophages to the site. IFNis one of the most 
well-known cytokines in the DTH response; IFNactivates macrophages and induces 
vascular adhesion molecule expression [31]. IFNwill be discussed in more depth in section 
1.3. 
The Johnin skin test for detection of MAP infection is a well-known CMI test modeled 
after the Mantoux tuberculin DTH test described above. Similar to the tuberculin skin test, 
ruminants are injected intradermally with 0.1 ml of 1-1.5 mg/ml purified protein derivative- 
johnin (PPD-J) and skin thickness is measured 72 hours post-injection [32-34]. Two 
advantages of the intradermal DTH test compared to other CMI testing methods, such as the 
IFNassay, include the ease of performance and the low costs associated with performing the 
test.  Studies have shown the Johnin DTH test to have >98% specificity in sheep and >93% 
specificity in dairy cattle [32, 33]. These investigations demonstrate good specificity in 
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MAP-free herds and flocks; unfortunately, this level of specificity has not been demonstrated 
in MAP-infected herds [34]. Investigations by Robbe-Austerman et al. studying sheep found 
the skin test was specific (98.7%) in non-infected flocks and sensitive (73.3%) in infected 
flocks; the sensitivity of the skin test exceeded that of serologic tests in infected flocks.  The 
cattle and sheep in infected herds and flocks have an increased positive skin test response but 
do not show infection grossly or histologically on necropsy examination [32, 33]. A 
proposed explanation for the poor sensitivity found in MAP-infected herds is the poor 
sensitivity of reference tests to identify every infected animal. It has also been theorized that 
uninfected animals with previous exposure respond to the johnin antigen; it has also been 
proposed that previously infected animals have recovered prior to necropsy evaluation. One 
investigation compared the CMI response in sheep by exposing sheep to antigen by either 
inhalation or oral ingestion of dead organisms. The findings suggested that a positive skin 
test result is not observed with exposure to dead organisms via inhalation or ingestion 
indicating that sheep are either no longer infected at necropsy or reference tests lack 
sensitivity [34]. Variability in specificity is not only observed between infected and non- 
infected populations but variation has also been shown in different batches of PPD-Johnin 
[32]. The influence of antigen batch on specificity has been previously demonstrated in 
studies investigating bovine tuberculosis using the M. bovis-PPD [35, 36]. 
The studies discussed above investigating johnin DTH skin test specificity did not 
include evaluation of vaccinated animals. Hines et al. evaluated the specificity of the johnin 
DTH skin test in MAP-vaccinated goats.  The study used a caprine model to look at various 
immune parameters following vaccination with 5 experimental, attenuated strains of MAP 
vaccine candidates compared to the commercial control vaccine, Silirum®. Intradermal skin 
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testing was performed at various time points before and after vaccination using three types of 
PPD: PPD-M. avium, PPD-M.bovis, and PPD-johnin. False-positive PPD skin test reactions 
were commonly observed in all groups for M. avium, including prior to vaccination. Post- 
vaccination, false-positive skin test reactions for  each of the PPD groups were observed as 
such: false-positives for PPD- M. avium in the control group, Silirum® vaccine, 3 of the 
experimental vaccine groups, false-positives for PPD-johnin in the Silirum® vaccine and 1 
experimental groups, and false-positives for PPD-M. bovis in the Silirum® vaccine and 2 
experimental groups. The results from this study showed that the commercial vaccine, 
Silirum®, as well as some of the experimental vaccines, produce false-positive results with 
all three PPD skin tests [37]. These findings are particularly significant when considering the 
utilization of DTH sites for testing and controlling bovine tuberculosis and paratuberculosis. 
Species’ variation within the cellular infiltrate observed at the intradermal DTH testing 
site is an important factor to consider when planning research studies that evaluate the cell- 
mediate immune response at DTH sites. In human tuberculin skin testing, 75-90% of the 
mononuclear cells present are CD4+ T lymphocytes and monocytes [38]. In contrast, the 
DTH cellular infiltrate of mice is comprised largely of neutrophils [39]. Gulliver et al. 
demonstrated a predominance of a mixed mononuclear cell infiltrate present in sheep similar 
to the human tuberculin DTH infiltrate [40]. In this investigation, the sheep with less 
extensive intestinal lesions had elevated levels of IFNin the serum and a greater degree of 
cellular infiltrate within the DTH site. However, sheep with more severe lesions, including 
lesions located outside of the gastrointestinal tract, had an absent to small cellular infiltrate at 
the DTH site, high serum anti-MAP antibody, and high serum IFNlevels [40]. This pattern 
observed in sheep within the DTH sites and intestinal tissues is consistent with the well- 
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described Th1 to Th2 transition in which IFNlevels drop with an increase in humoral 
antibody response and lesion progression. 
Review of the current literature revealed histological analysis and cell identification in 
DTH sites of cattle has not been extensively evaluated. In an investigation with Holstein 
calves, Plattner et al. compared the skin thickness of DTH sites between naïve, MAP- 
infected, and MAP-vaccinated cattle. As expected, MAP-infected and MAP-vaccinated 
calves had significantly thicker DTH sites. In comparison to the ovine study described above 
that histologically evaluated DTH sites, this investigation in cattle by Plattner et al. collected 
cellular infiltrate via retrieval and analysis of a biopolymer containing MAP antigen placed 
subcutaneously for 48 hours; in theory, this antigen and biopolymer study mimicked a DTH 
skin test. Using flow cytometry, the phenotypes of the T cells retrieved were identified; it 
was found that δ T cells were observed at greater frequency 7 days post infection versus 30 
days post infection, in which CD4+ T cells were the predominant cell type. IFNwas also 
measured and levels were higher in polymer containing MAP compared to control sites. 
IFN was also higher at polymer sites 30 days post infection compared to 7 days post 
infection [41]. These findings may indicate that δ T cells are initial responders in bovine 
DTH sites and generate significant amounts of IFNfor activation of CD4+ T cells, dendritic 
cells, and macrophages. The described species’ variation of cellular infiltrate observed in 
DTH sites is important to note when using different models for MAP infection/vaccination 
studies. 
 
 
IFNand IL-10: Cytokines involved in MAP immune response 
 
As discussed above, the role of the immune response, particularly the Th1/Th2 responses, 
during initial infection and disease progression is highly complex. A better understanding of
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the definitive markers of protective immunity, active infection, and latent, subclinical 
infection is essential to advance vaccine development as well as prevent, diagnose, and 
control disease.  The Th1 and Th2 responses are often measured by the cytokines they are 
known to produce, such as IFNand IL-10 respectively. Classical Th1, pro-inflammatory 
cytokines include IL-1α, IL-1β, IL-6 IL-12, IL-23, IL-17, TNFα, and IFN[42]. IFNis a well-
known, well-studied, Th1 cytokine of mycobacterial infections and was the cytokine used 
most extensively in these chapters to evaluate the Th1 response. The production of Th2 
cytokines is associated with a humoral response in which proliferation of B cells and 
inhibition of the Th1 response is observed. Classical Th2, anti-inflammatory cytokines 
include IL-4, IL-5, and IL-10 [43]. IL-10 and its role in the MAP immune response is an 
increasingly popular area of investigation; IL-10 was the anti-inflammatory cytokine used to 
evaluate Th2 responses in chapters 2-4. 
IFN is a Type II interferon secreted by CD4+ Th1 cells, CD8+ T cells, δ T cells, APCs, 
and natural killer cells [44]. In more recent investigations, other cells including B cells, 
NKT cells, and neutrophils have been shown to secret IFN[45-48]. IFNis a crucial player in 
the Th1 response and protection against intracellular pathogens such as mycobacteria. 
IFNis known to promote innate cell-mediate immunity by activation of NK cell effector 
functions [49]. Through T cell:APC interactions, IFNfunctions to promote specific 
cytotoxic immunity. Finally, one of the more important functions of IFNincludes 
macrophage activation. Kamijo et al. demonstrated the significance of IFNin mycobacterial 
infection using mice lacking the IFNreceptor. Mice with a disruption of the IFNreceptor 
gene and wild-type mice were inoculated with M. bovis; infection with M. bovis was only 
lethal for the mice without a functional IFNreceptor [50]. Both mice and humans 
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demonstrate a higher susceptibility to infection with intracellular pathogens and non- 
pathogenic mycobacteria, respectively, when mutated IFNgenes are present [24, 51]. 
IL-10 is an anti-inflammatory cytokine also known as cytokine synthesis inhibitory factor 
 
(CSIF) [52]. Produced by macrophages, B cells, and T cells, IL-10 is best known for its 
strong anti-inflammatory activities [53]. The expression of IL-10 is crucial for controlling 
immune responses after infection. Knockout studies in mice with defective IL-10 
demonstrated an uncontrolled level of IL-12 and IFNcompared to wild-type mice; these IL- 
10
-/- 
mice also exhibited a significant increase in the Th1 cell population in their colon 
 
mucosa. The findings of this study indicated the importance of IL-10 in regulating immune 
responses, particularly in the gastrointestinal tract [54]. Specific to mycobacteria, IL-10 has 
been shown to be released following phagocytosis of pathogenic M. tuberculosis [55]. 
Widdison et al. also showed a correlation between enhanced IL-10 levels and progression of 
 
M. bovis in cattle [56]. Several studies have looked at the effects of IL-10 suppression on 
IFNlevels in antigen-stimulated peripheral blood from animals infected with different 
mycobacterial pathogens; the study results showed enhanced IFNlevels in the whole-blood 
IFNassay when anti-IL-10 antibody was removed[57, 58]. 
Prior research of cytokine profiling in MAP infection has focused on peripheral blood 
 
immune responses, as well as sites of infection such as ileum and lymph node [15, 59]. There 
have been several papers focused on cytokine expression profiles in cattle, sheep, and goats 
[16, 60, 61]. One example is the extensive work by Coussens et al. and their examination of 
the gene expression of 13 different cytokines in PBMCs, intestinal lesions, and mesenteric 
lymph nodes of MAP-infected and naïve cattle. The findings in the PBMCs demonstrated 
that only IL-10 gene expression was increased with MAP antigen stimulation of the PBMCs 
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in subclinical cattle, and the levels of IFN, IL-1α, and IL-6 were reduced with MAP antigen 
stimulation of the PBMCs. These findings provided supportive evidence for the enhancement 
of anti-inflammatory cytokines and suppression of pro-inflammatory cytokines when cells 
were stimulated with MAP antigen. Ileal tissues exhibited greater expression of pro- 
inflammatory cytokines in infected compared to naïve cattle [15]. This pro-inflammatory 
response observed in the tissues, along with the Th1 suppression observed in stimulated 
PBMC of infected cattle, is a well-known finding in mycobacterial research [15, 16, 58, 60- 
62]. 
The cytokine expression profiles in PBMCs and tissue samples provide beneficial 
information on mycobacterial immune responses and diagnostic markers at the systemic and 
gastrointestinal level. However, minimal current literature exists on the immune responses, 
cellular infiltrate, and cytokine profile within the intradermal testing site in cattle. Human 
studies have used immunohistochemical evaluation to quantify the cells containing different 
cytokines at several time points post-PPD intradermal injection in Bacillus Calmette–Guérin 
(BCG)-vaccinated individuals. Cells containing IL-1α, IL-1β, IL-6, IFN, and TNFα were 
observed as early at 6 hours after PPD injection. IFNwas observed in the highest frequency 
of cells and 33% of cells were IFNpositive at 48 hours; however, by 7 days post intradermal 
injection IFNhad dropped to 3% of total cells. Using dual fluorescent labeling, 
IFNpositive cells were shown to be CD3+ T cells compared to the TNF-a, IL-l and IL-6 
positive cells which were CD68+ macrophages [63]. A better understanding of the 
expression of in vivo cytokines in a MAP-induced DTH reaction may provide helpful 
information about the cell-mediated immune response observed in vaccinated and naïve 
cattle. 
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MAP vaccination: Introduction 
 
The current strategies to control MAP infection rely on prevention of new infections, 
particularly during the neonatal period [1]. These control strategies include management 
practices to improve calving hygiene and rearing, test-and-cull strategies, and vaccination. 
More hygienic calving practices and test-and cull-strategies are known to reduce MAP 
infection in herds; however, both of these strategies require long-term management and 
producer dedication before economic benefits are observed [64]. The economic costs of test 
and cull strategies have been shown to be higher than their financial benefits [65]. 
Vaccination is known to decrease MAP fecal shedding and reduce numbers of clinically 
affected cattle [66]. Field investigations that have evaluated MAP vaccination on MAP- 
infected herds found that vaccination strategies reduced fecal shedding of MAP and the 
number of cows with clinical disease in the herd [67]. One field study also found MAP 
vaccination was cost-efficient in herds with a high prevalence of infection [68]. However, 
most of the research on cost to benefit analysis of MAP vaccination has been based on 
mathematical models and hypothetical vaccines with superior protection [64]. Mathematical 
models are often used because the long incubation period of MAP hinders a controlled 
clinical trial [69]. A critical need exists for a more economical strategy to prevent and control 
Johne’s disease in cattle herds. MAP vaccination has the potential to reduce economic losses 
and control MAP infection; however, a more efficient model to screen future vaccine 
candidates is needed. The focus of the research in chapters 2-4 is based on this need and 
includes the development and evaluation of a potential device used for in vivo CMI analysis 
and vaccine candidate screening. 
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Current and future vaccines 
 
The current approved vaccine for MAP in the United States is the killed bacterin 
product, Mycopar®, available on a conditional basis with state veterinarian approval. 
Mycopar® is made by Boehringer Ingelheim Vetmedica Inc. [70]. The complication of this 
vaccine is the potential for MAP vaccination to cause a positive M. bovis intradermal test 
further requiring the effort and expensive of a comparative cervical test. Therefore, it has 
been hypothesized that widespread vaccination of MAP could largely affect the M. bovis 
surveillance program [64]. Silirum®, manufactured by Zoetis, and Gudair®, produced by CZ 
Veterinaria, are two commercially available, inactivated, whole-cell vaccine preparations; 
currently, these vaccines are not available in the United States [71]. 
Despite the current limitations and drawbacks, vaccination still holds the potential to 
control or eradicate Johne’s disease. A great need exists for the development of new vaccine 
candidates with improved efficacy; vaccines are needed that prevent bacterial transmission 
and fecal shedding. Also, an ideal vaccine candidate would not form an injection site 
granuloma that is currently observed following MAP vaccination [72-74]. It would be 
beneficial to produce future candidates that demonstrate immune protection specific to the 
MAP immune response without the current cross-reactivity that interferes with M. bovis 
control and surveillance. 
Research indicates that subunit vaccines may prove to have fewer drawbacks than the 
currently available whole-cell vaccines. Recent studies of subunit vaccines showed a 
reduction in granuloma formation with injection; however, improvements in protection 
against MAP infection were not observed in these murine, bovine, or caprine models [75-77]. 
Koets et al. demonstrated successful use of recombinant MAP Hsp70 as a subunit vaccine 
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against bovine paratuberculosis by reducing shedding of bacteria in feces during the first two 
years following experimental infection [75]. Santema et al. has shown that the HSp70/DDA 
subunit vaccine does not interfere with current M. bovis diagnostic assays. In addition, 
Santema et al. discovered that by performing an extra step during the ELISA assay, 
distinction between infected cattle and cattle vaccinated with Hsp70/DDA can be achieved 
through this assay; simple removal of the Hsp70/DDA vaccination induced antibodies will 
reestablish the specificity of the ELISA test [78]. The absence of granuloma formation and 
lack of M. bovis test interference are significant benefits to subunit vaccines; however, these 
new candidates have not yet demonstrated an improvement in MAP protection over the 
commercially available vaccines. 
In addition to the subunit vaccine studies, there has been an increased research spike 
in the development of live-attenuated vaccines. Advantages of this type of vaccine include 
strong stimulation of innate and adaptive immune responses and low cost of manufacturing 
[3]. In order to attenuate the virulence of MAP for use in vaccines, various mutants have 
been developed for investigation of their efficacy at providing protection against infection. In 
previous genome studies, Hsu et al. identified sigH as a mycobacterial gene regulator in 
MAP [79]. Ghosh et al. utilized this gene identification to evaluate the protective efficacy of 
a vaccine candidate with a sigH mutant compared to a wild-type MAP K10 strain. Bacterial 
burden was greatly reduced and IFNlevels significantly elevated in the sigH mutant vaccine 
candidates. The sigH mutant vaccine study demonstrated superior protection in comparison 
to the wild-type strain [80]. In addition to the sigH mutant study by Ghosh et al., other 
researchers have also used the murine model as a screening test for various MAP vaccine 
mutants [81, 82]. For instance, Settles et al. used the murine model to investigate two vaccine 
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mutants, pgs1360 and pgs3965, that contained mutations in separate genes. After MAP 
challenge, both vaccine candidates showed reduced bacterial loads within organs compared 
to control mice [82]. Shippy et al. further evaluated the sigH and pgs mutants in a caprine 
model. Both mutant vaccines demonstrated reduced lesions and low bacterial load within 
intestinal tissues compared to naïve goats and goats vaccinated with an inactivated vaccine. 
One of the mutant vaccines was shown to eliminate fecal shedding, which would be highly 
beneficial to the control and eradication of MAP infection [6]. In summary, the development 
of new vaccine candidates is promising for future use in Johne’s disease control programs; 
however, this area of research is slow to progress, largely due to the financial constraints and 
lengthy duration of vaccine testing models. 
 
 
Animal models and vaccine candidate screening 
 
Multiple factors hinder current investigative efforts to improve the efficacy of MAP 
vaccines. For example, high costs are incurred during vaccine trials using natural hosts such 
as sheep, goats, cattle, and deer. Secondly, the characteristic long latent period of infection 
makes screening vaccine candidates in natural hosts an extensive and long process. Finally, 
the lack of standardized animal challenge models makes comparison of new candidates in 
different vaccine trials highly problematic [71].  Fortunately, efforts toward standardizing 
animal challenge models and vaccine trials for MAP have been implemented, benefiting the 
research and development of novel vaccines. Supported by the Johne’s Disease Integrated 
Project (JDIP), a committee of MAP researchers was formed called the JDIP Animal Model 
Standardization Committee (AMSC), and these 16 members collaborated to form guidelines 
and parameters for vaccine efficacy studies in models of different species. Based on expert 
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consensus, a list of parameters for each MAP host model was formulated [83]. In a paper by 
Bannantine et al., the standardized testing parameters and models were used to evaluate 22 
vaccine candidates developed across the United States and New Zealand. The studies utilized 
the JDIP Animal Model Standardization Committee guidelines to establish a 3-phase trial: 
Phase 1 evaluated survival in bovine macrophages, and the mutants that showed a reduced 
pathogenicity or vitality advanced to the Phase II mouse trial. In Phase II, eight attenuated 
vaccines were used in a murine model and evaluated for bacterial load in tissues at varying 
time points after MAP challenge. In the murine model, 5 of the 8 candidates showed bacteria 
that did not survive in the liver and spleen. Finally, Phase III was conducted in goat kids. In 
this goat model, a reduction in incidence and severity of infection was observed in some 
vaccine strains; however, none of the vaccines eliminated fecal shedding [71, 81]. The results 
of the study indicate that the use of the 3-phase, macrophage to mouse to ruminant platform 
may need adjustments, particularly in the macrophage and mouse models where evidence of 
attenuation in vitro and within an unnatural host, respectively, does not appear to predict 
natural host protection [71, 81, 84].  In summary, cell culture and mouse trials may not be 
ideal models for screening vaccine candidates to show protective immunity in a natural host. 
However, the efforts by the JDIP Model Standardization Committee to define parameters and 
standardize natural host models will prove beneficial for vaccine candidate comparison in 
trials across different research laboratories. Future development of approaches to make 
vaccine trials more efficient and economical using natural host models are necessary to 
facilitate the research being generated on novel MAP vaccine candidates. 
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Abstract 
 
Improved vaccine candidates are increasingly sought for control and ultimate elimination 
of Mycobacterium avium subsp. paratuberculosis (MAP) from cattle herds. A current 
obstacle in MAP vaccine development is the expense and lengthy incubation period 
associated with vaccine-challenge experiments in the bovine model. To aid in the 
development of successful MAP vaccines, an initial screening test that evaluates the in vivo 
immune response after MAP challenge would provide knowledge of the vaccine’s efficacy in 
a shortened time frame. In this study, we discuss the development of a device placed within 
the subcutaneous tissue for in vivo collection of antigen-specific cytokines and cellular 
infiltrate that can be measured ex vivo upon retrieval. We assessed histologic sections and 
measured cytokine levels in implant collagen retrieved from the neck subcutis of naïve and 
MAP-vaccinated cattle.  We found the collagen containing MAP antigen showed a markedly 
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increased cellular infiltrate similar to the increase in cellular infiltrate observed with delayed- 
type hypersensitivity (DTH) responses. Detectable concentrations of IL-10 and IFN-were 
extracted from the retrieved collagen and IFN-was significantly higher in the collagen 
containing MAP antigen implanted into MAP-vaccinated calves. 
 
 
Introduction 
 
Mycobacterium avium subspecies paratuberculosis (MAP) is the etiologic agent of 
Johne’s disease, a chronic, granulomatous enteritis of ruminants often resulting in 
progressive diarrhea, weight loss, and loss of conditioning [1]. Neonates are most susceptible 
to infection, and the fecal-oral route from cow to calf is considered the primary mode of 
transmission [2]. Following MAP infection of calves, a prolonged incubation period (>2yrs) 
develops that is characterized initially by variable cell-mediated (Th1-type) immunity [3, 4]. 
During this stage of infection, clinical signs and bacterial shedding do not occur; detection of 
these animals is therefore difficult. A proportion of infected cattle will eventually progress to 
clinical disease where the Th1 response wanes and an ineffective Th2 response develops [2, 
3, 5, 6]. Treatment is not typically an option due to the high cost of antimycobacterial 
therapeutic agents combined with the high doses required for long treatment periods. 
Due to difficulty in identifying MAP-infected animals, vaccination is increasingly looked 
to for control and elimination of MAP from cattle herds. The current commercially available 
vaccines against Johne’s Disease, Mycopar® (Boehringer Ingelheim Vetmedica, Inc.), 
Silirium® Vaccine and Gudair® Vaccine (Zoetis AU), can delay and decrease clinical 
disease; however, vaccination does not prevent fecal shedding and transmission [7, 8]. The 
ideal vaccine for MAP infection would induce a sustained cell-mediated response that 
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prevents bacterial shedding and disease progression [4]. Development of new vaccines 
against paratuberculosis is an area of active research with protein subunit, DNA, and 
attenuated live vaccines being investigated as potential candidates [4, 7, 9]. An obstacle to 
development of new effective vaccines is the difficulty in testing vaccine candidates. This is 
due to the long incubation period following infection, which makes standard vaccine- 
challenge studies time-consuming and expensive. Moreover, alternative models including 
rodents and cell culture systems do not accurately predict the bovine immune response to 
vaccines [4, 9]. 
Detection of cell-mediated immune responses is a central component in testing new 
vaccines against mycobacterial infections. Methods for detection of cell-mediated immune 
responses in cattle include a delayed-type hypersensitivity (DTH) intradermal skin test and 
the interferon gamma (IFN-) release assay [3, 10, 11]. In both of these assays, there can be 
limited specificity due to antigen cross reactivity with nonpathogenic mycobacteria. The skin 
test provides a yes/no answer to the presence of a cell-mediated immune response, but 
intermediate results are common and difficult to interpret. The IFN-y release assay will allow 
for quantification of a single cytokine. However, the accuracy of the assay can be reduced by 
multiple factors including variation of the antigen preparations (PPD), loss of IFN-y signal 
during transit from the field to the lab, and artifacts induced from ex vivo culture conditions 
required for antigen stimulation. 
Our laboratory set out to improve detection of cell-mediated immune responses to MAP 
vaccines in calves. Our strategy was to develop a platform that directly measures cell- 
mediated immunity within the animal. This platform uses a removable subcutaneous implant 
that houses MAP antigens. The cellular and cytokine responses to the antigens are retained 
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within the implant, and are assessed following implant removal. The rational for this 
approach is that it will measure the immune response at the actual site of antigen exposure in 
the living animal, thereby reflecting the true in vivo immune response. In this manuscript we 
describe the development and use of this assay. We demonstrate differential immune cell 
infiltrates and cytokine production in MAP vaccinated calves using the removable implant 
and compare this to a standard IFN-release assay. 
 
 
Theory 
 
The overall principle of this method is to measure immune variables associated with 
the delayed-type hypersensitivity (DTH) response within the subcutis of calves vaccinated 
for MAP. Our platform is a cell-permeable implant that contains a collagen-based polymer 
admixed with MAP antigens. The implant is placed in the subcutis for 48 hours, similar to a 
standard DTH skin test. The implant creates a self-contained environment for the immune 
response that retains recruited immune cells and secreted cytokines that, upon removal, can 
be measured in the laboratory using the methods outlined below. We expect that measuring 
multiple immune variables in vivo will enhance the ability to assess an animals’ response to 
vaccination. 
 
 
Materials and Methods 
 
Animals and vaccination 
 
Four Holstein bull calves that were approximately 250-300 pounds were procured by 
Laboratory Animal Resources at Iowa State University in Ames, Iowa. Calves were housed 
in an outdoor research facility and divided randomly into the following two groups:  naïve 
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(n=2) and MAP vaccinated (n=2). Vaccinated animals were vaccinated in the ventral neck 
region with Mycopar®, a whole cell inactivated bacterin (Boehringer Ingelheim Vetmedica, 
Inc., Saint Joseph, Missouri), per the manufacturer’s instructions. All animal protocols were 
approved by the Institutional Animal Care and Use Committee (IACUC) at Iowa State 
University (Ames, IA, USA). 
 
 
PureCol® EZ Gel and MAP Antigen 
 
The polymer used in this experiment is a Type I bovine collagen (PureCol® EZ Gel, 
Advanced BioMatrix, San Diego, CA). PureCol® EZ Gel is a commercially available, pre- 
formulated, purified Type I bovine collagen at 5mg/ml concentration that forms a firm gel at 
37C. The collagen contains CMEM/F-12 medium with L-glutamine and L-alanine-L- 
glutamine. PureCol® EZ Gel (hereafter referred to as collagen) was stored at 4C in liquid 
form. A commercial preparation Mycobacterium paratuberculosis purified protein derivative 
johnin (PPD-J) intradermic tuberculin (NVSL, Ames, IA, USA) was used for this study and 
stored at 4C. Johnin PPD is a solution of phenolized phosphate buffer and tuberculoprotein at 
a concentration of 1.0mg/ml. Prior to implantation, collagen containing 30 percent PPD-J or 
an equal amount of sterile saline, as a control, was loaded into the mesh lining within the 
cylinder of the implant. Implants were then incubated at 37C for at least one hour allowing a 
firm gel to form. 
 
 
Implantation procedure 
 
Calves were restrained with the use of halter, chute, and an adjustable head gate. The 
right and left lateral necks were sterilely prepped and 3ml of 10mg/ml lidocaine was 
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dispersed into a localized area of approximately 4cm by 4cm. A 0.5cm incision was made via 
scalpel blade followed by insertion of the implant using the implantation device leaving the 
cylindrical portion of the implant in the subcutaneous tissues with the retrieval pin remaining 
external. To adequately stabilize the device, a single suture was placed through the epidermis 
and around the retrieval pin. Two implants were placed in each animal; the first, a control 
implant, containing only collagen and a second implant containing collagen and MAP 
antigen.  The implants remained in the calves for a duration of 48 hours. 
 
 
Implant retrieval and collagen processing 
 
Implants were removed via retraction on the retrieval pin and transported back to the 
laboratory. A single interrupted suture was placed in the skin to close each implant site. The 
nylon mesh and associated collagen plug were removed from the stainless-steel housing of 
each implant. The collagen was then removed from the nylon mesh lining. For 
histopathology, a section of collagen was placed in 10 percent neutral buffered formalin and 
processed routinely for hematoxylin and eosin (H&E) staining. 
To quantify the cellular density within the fixed collagen sections, total nucleated cell counts 
(TNCC) were performed at high magnification (100x objective); each group (n=2) had a total 
of 10 fields counted (5 fields per individual implant). For cytokine analysis, the remaining 
collagen was cooled on ice and thoroughly minced in complete RPMI media (cRPMI, Life 
Technologies, Grand Island, NY, USA). The supernatant was then collected and stored at - 
20C for future cytokine analysis (n=2 implants per group). 
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Blood collection and cell culture 
 
Four blood samples were collected from naïve (n=2) and MAP vaccinated (n=2) 
calves. Ten milliliters of whole blood was collected in acid citrate dextrose via jugular 
venipuncture and peripheral blood mononuclear cells (PBMC) were isolated using buffy coat 
density centrifugation. PBMC were suspended in cRPMI medium supplemented with 10% 
(v/v) FBS, 1% L-glutamine, 1% sodium pyruvate, 1% non-essential amino acids, 2% MEM 
essential amino acids, 0.1% penicillin-streptomycin, and 0.004% 2ME (all purchased from 
Life Technologies). Cells were diluted to a final concentration of 5x10
6 
cells/well in a 96- 
 
well plate and stimulated with Concavalin A (Sigma-Aldrich, St. Louis, MO, USA) at 
2ug/ml, Johnin PPD (National Veterinary Services Laboratory, Ames, IA, USA) at 10ug/ml, 
or cRPMI medium for 24 hours at 37C and 5% CO2. Supernatants were collected and placed 
at -20C for future cytokine analysis. 
 
 
Luminex® multiplex assays 
 
Supernatants from the implant collagen and MAP antigen-stimulated PBMC were 
incubated with magnetic beads in a 96-well plate at room temperature for two hours. 
Magnetic beads (MC10062-01, MC10026-01, Bio-Rad Laboratories Inc, Hercules, CA, 
USA) were pre-conjugated with IL-10 and IFN-capture antibody (MCA2110, MCA2112, 
Bio-Rad). Biotin-labeled IL-10 and IFN-detection antibodies (MCA1783B, MCA2111B, 
Bio-Rad) were added and incubated for one hour followed by a 30-minute incubation with 
eBioscience
TM 
Streptavidin PE (Invitrogen, Thermo Fisher Scientific Inc, USA). The mean 
 
fluorescence intensity and bead classification was determined via Bio-Plex®200 reader (Bio- 
Rad) and compared to a standard curve to derive cytokine concentrations of each individual 
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sample.  The following proteins were used to create a standard curve:  recombinant bovine 
IFN-and recombinant bovineIL-10 (PBP007A, PBP016A, Bio-Rad). 
 
 
Graphs and analysis 
 
Graphs were made using GraphPad Prism 7 (La Jolla, CA). All data are shown as 
mean + standard deviation (SD). Normality tests (D’Agostino-Pearson omnibus normality 
test) were performed on the datasets, and in some instances, the data did not have a normal 
distribution; therefore, nonparametric tests were used for all analyses. Differences between 
MAP antigen usage for TNCC (Fig. 6) and cytokine levels in collagen (Fig. 7) were assessed 
using Kruskal-Wallis test for multiple comparisons. Due to small experimental group size 
(n=2), statistical analysis could not be performed on cytokine levels measured from 
stimulated PBMC (Fig. 8). 
 
 
Results and discussion 
 
Implant design 
 
The goal of this study was to create a removable implant that would be a self- 
contained environment for cell-mediated immune responses to occur within the subcutaneous 
tissue of cattle. Immune mediators contained within the implant would then be measured 
after it was removed from the animal. In this way we would measure in vivo immune 
responses at the sites of vaccination. We designed an implant based on our previous work 
directly placing Matrigel
TM   
mixed with MAP antigens into the subcutaneous tissue of calves 
 
[12]. In these earlier studies we were able to detect cell-mediated immune responses within 
the Matrigel
TM 
after its removal from the calf. However, recovering Matrigel
TM 
required 
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surgical biopsy. We needed to create an implant that could be rapidly placed and removed 
from the animal. 
The designed implant device (Fig. 1) consists of an outer stainless-steel housing that 
is 7cm x 4mm. At one end of this housing there is a solid 3.5cm solid retrieval pin that 
attaches to a 4.5cm hollow cylinder. Two rectangular windows are present along the length 
of the hollow cylinder portion of the implant (Figure 1, insert). A nylon mesh screen, with 
30um pore size, lines the interior of the cylindrical portion of the implant and communicates 
with the exterior of the implant via the rectangular windows. The nylon mesh screen 
surrounds a core of up to 350ul of collagen and directly opposes the two windows of the 
cylinder. The collagen contains the MAP antigen (here we used PPD-J). The implant is 
designed to allow recruitment and migration of immune cells across the nylon mesh into the 
collagen core where the MAP antigen is located.  An implantation device was developed for 
this implant (Fig. 2), which places the implant beneath the skin into the subcutaneous tissue. 
For this study, the pin was left on the exterior of the animal (Fig. 3) and secured with single 
suture. The implant was removed by gentle retraction on the retrieval pin. In subsequent 
studies, the implant was buried in the subcutis and the incision closed with suture (not 
shown). 
We have used two types of collagen in the implant, PureCol® EZ Gel and BD 
Matrigel
TM 
Matrix and have measured cytokines and cellular infiltrates from both. BD 
Matrigel
TM 
Matrix, is a solubilized basement membrane preparation extracted from the 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma. PureCol® EZ Gel is a purified Type I 
collagen from a bovine source. Matrigel
TM 
is thermoreversible and after cooling the gel 
readily returns to a liquid state. This facilitates recovery of recruited immune cells and 
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proteins from the implant. However, cattle can develop an immune response to the mouse 
proteins in the Matrigel
TM 
with repeated use. PureCol® EZ is purified bovine collagen that is 
non-immunogenic and is well suited for repeated use in longitudinal studies. The PureCol® 
EZ is not thermoreversible and requires additional processing (mincing) to recover intact 
cells and cytokines. PureCol® EZ and Matrigel
TM 
can be fixed and processed as any solid 
tissue for histopathology. We have found that the antigen (PPD-J) mixes well in both types of 
collagen.  As a negative control we use an implant with collagen but no antigen for detection 
of baseline immune responses to the collagen alone. The data shown in this manuscript are 
from implants containing PureCol® EZ. 
 
 
Implant placement into MAP vaccinated calves 
 
We used the implant to detect cell-mediated immune responses in Mycopar®- 
vaccinated calves. MAP vaccination with this product leads to a strong cell-mediated 
immune response in calves 1-2 weeks post vaccination [13]. One group of calves was 
vaccinated with Mycopar® and a second group was given a sham vaccine of saline. Two 
weeks post-injection, vaccinated calves developed an anticipated firm swelling at the 
injection site (vaccine granuloma) [14]. Two weeks post-vaccination two implants were 
placed in each calf, one with collagen containing MAP antigen and one with collagen only. 
Calves were restrained in a chute with a head gate for implant placement and removal. With 
the aid of lidocaine local analgesia, we did not experience any difficulty placing the implants. 
The implantation process, including sterile preparation of the neck, took approximately 10-15 
minutes per calf. The implants remained in the subcutis for 48 hours and were then removed. 
All implants were recovered and calves did not demonstrate any adverse effects. After 
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implant removal, the steel housing was separated from the nylon and collagen core. The 
nylon screen was then separated from the collagen (Fig. 4). Figure 4A demonstrates the 
nylon mesh surrounding the collagen after removal from the steel housing. Figure 4B 
demonstrates opening of the nylon screen and removal of the collagen. The collagen was 
then split into two equal halves; the first half being processed for histopathology and the 
second for cytokine analysis. 
 
 
Histological evaluation of immune cell recruitment into the implant 
 
After removing the collagen (Figure 4B) from the implant it is processed to slides 
using the same procedures as any solid tissue. Histologic sections of the collagen recovered 
from the calves are shown in Figure 5. These images demonstrate that when antigen is not 
present in the collagen, regardless of vaccination status, there is minimal cellular infiltrate 
into the collagen (Fig. 5 A, C). In contrast, in sections where MAP antigen (PPD-J) was 
included in the collagen, a greater cellular infiltrate was observed (Fig. 5 B, D). The density 
of recruited cells is significantly higher (Fig. 6) in implants containing MAP antigen that 
were placed and retrieved from vaccinated calves. This demonstrates antigen dependent 
immune cell recruitment to the implant and immune cell migration through the nylon mesh 
into the collagen core.  Based on morphology, this cellular infiltrate consisted of numerous 
neutrophils intermixed with fewer lymphocytes and macrophages. 
We hypothesized that the infiltrating cells would be in similar proportions as a 
delayed-type hypersensitivity (DTH) reaction to standard mycobacterial skin testing with 
lymphocytes and macrophages being the dominate cell types. Skin testing is an in vivo test 
commonly used to identify cell-mediated immune responses to multiple mycobacterial 
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infections including M. tuberculosis, M. bovis, and M. leprae. The skin test uses a purified 
bacterial protein preparation (PPD) as antigen. PPD is injected directly into the dermis, and 
sensitized animals will develop a DTH reaction that is maximal 48-72 hours post injection. 
PPD preparations vary according to the mycobacterial species that is being tested. Skin 
swelling size is the sole parameter measured, but histopathology of the injection site has been 
evaluated. Previous investigators have demonstrated that the early microscopic features of 
the DTH in skin tested M. bovis infected cattle include a cellular infiltrate into the dermis that 
is predominately comprised of neutrophils and mononuclear cells, and as the reaction 
progresses the degree of mononuclear cells increases [15]. While neutrophils were the main 
cell detected in the collagen in this study, it is possible that lengthening the duration of time 
in which the implant device is placed from 48 to 72 hours would increase the percentage of 
mononuclear cells.  In future studies we will use immunohistochemistry for lymphocyte and 
macrophage markers to further quantify the mononuclear cell infiltrate. 
 
 
Cytokine analysis from implants and from antigen stimulated peripheral blood  
mononuclear cells 
We next measured cytokine concentrations in the implants recovered from naïve and 
vaccinated calves. After implant removal, the collagen was cooled, minced, washed and the 
supernatants collected. A bead-based multi-analyte profiling assay (Luminex®) was used to 
measure cytokines within the collagen. We hypothesize that measuring multiple cytokines 
will provide more information on the immune response over single analyte tests, such as the 
IFN-γ release assay. For this study we selected IFN-and IL-10. IFN-is a Th1 cytokine and a 
central driver of innate and adaptive immunity against intracellular pathogens [16]. 
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Production of IFN-occurs early in the course of MAP infection and MAP vaccination. In 
MAP-vaccinated cattle, it has been shown that MAP specific IFN-production by PBMC 
occurs by seven days post-vaccination and remains elevated for up to one year [13]. IL-10 is 
known to suppress macrophage activation and down-regulate inflammatory cytokines [17]. 
IL-10 has been shown to be suppressed in calves given a modified live MAP vaccine [18]. A 
ratio of IL-10 to IFN-has been used to characterize the immune response to mycobacterial 
infection in humans and correlates to severity of clinical disease [19]. 
Cytokines were quantified using standard curves for bovine recombinant IL-10 and 
IFN-. The highest concentration of IFN-(P< 0.05) was detected in collagen containing MAP 
antigen that had been placed in MAP vaccinated calves. IFN-was not detected in naïve 
calves or from implants without MAP antigen (Fig. 7A). This data suggests that the implant 
is able to elicit antigen-dependent cytokine production within the animal. It also 
demonstrates that the collagen in the implant retains the generated cytokines, which can be 
measured after implant removal. IL-10 (Fig. 7B) was detected at higher concentrations than 
IFN-(Fig. 7B note y-axis scale difference). However, this was not antigen or vaccine- 
dependent. In future studies we will continue to assess cytokines that have been shown to be 
associated with immune responses to mycobacterial vaccination including TNFα, IL-17, IL- 
23, IL-6, IL-4, and IL-1β. 
We compared the cytokine concentrations from our implants to cytokine release 
assays using PBMC collected from calves immediately prior to implanting. IFN-and IL-10 
production were measured from cultured PBMC that were stimulated with PPD-J, media or 
Concanavalin A. As expected, only the PBMC from vaccinated calves showed IFN-
 production after stimulation with PPD-J (Fig. 8A, B). The pattern of cytokine production 
in 
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PBMC followed that from the implants where IFN-was detected only in implants with 
antigen placed in vaccinated animals.  Differences in IL-10 concentrations from stimulated 
PBMC were not observed between the calves, similar to the implant cytokine data. This data 
demonstrates comparable results for cytokine production in the implant collagen and 
cytokine release assays, and provides proof of principle for using this implant to detect 
immune responses in vivo. 
 
 
Conclusions 
 
We have developed an implant that serves as a self-contained environment within the 
animal where immune responses to a given antigen occur. Parameters of this immune 
response can be measured upon implant removal. This study describes placement and 
recovery of implants from the subcutis of naïve and MAP-vaccinated cattle. We measured 
cellular recruitment into the collagen of the implant using histopathology, as well as cytokine 
concentrations in the collagen using a multiplex immunoassay method. We show increased 
immune cell infiltrate into the implants placed in MAP-vaccinated calves and a correlating 
increase in the concentration of IFN-γ. To our knowledge, this is the first MAP-specific in 
vivo measurement of IFN-. We also detected IL-10 in all implants, but neither antigen or 
vaccination status influenced IL-10 concentration.   The advantage of this system is that 
multiple parameters can be evaluated simultaneously to more accurately assess the in vivo 
immune response. The parameters included in the assay can be tailored to each study and 
increase the versatility of the system. 
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Figure 1: Implant Design. The implant holds 300ul of polymer. It has a window 
(insert) lined by a nylon mesh screen (black arrow). The implant is removed by 
retraction of a steel pin attached at one pole (red arrow). 
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Figure 2: Implant placement device. This device is used to inject the implant into the 
subcutis. 
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Figure 3: Implant placed in the calf. The removal pin (white arrow) in this experiment was 
left on the exterior of the animal and would be secured with a suture. The housing containing 
the collagen polymer is within the subcutis. 
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Figure 4: Removal of polymer from implant. 4A – the nylon mesh (black arrows), which 
surrounds the polymer is pulled from the end of the implant. 4B – the nylon mesh is opened 
and the polymer (orange arrow) is removed for further processing. 
4B 4A 
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Figure 5 (20x): Immune cell recruitment into collagen. A – collagen with no MAP antigen 
recovered from a naive calf. B – collagen with MAP antigen recovered from a naive calf. C – 
collagen with no MAP antigen recovered from a vaccinated calf (insert, 100x). D – collagen 
with MAP antigen recovered from a vaccinated calf. These images demonstrate that cellular 
recruitment was strongest in the collagen recovered from vaccinated calves where MAP 
antigen was included in the collagen. 
D C 
B A 
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Figure 6: Number of cells observed within collagen sections. The number of cells per 
high-powered magnification field (100X) was counted. 5 fields from each collagen section 
were examined to determine the mean number of cells recruited into the collagen implanted 
into naïve and vaccinated calves. n = 2 implants per group (10 fields counted per group). 
Data are presented as mean ± SD. 
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Figure 7: Cytokine levels from implant collagen. A – IFN-levels are highest in 
vaccinated calves where the collagen contains MAP antigen. B – IL-10 was detected in all 
implants. There were no differences in IL-10 concentrations in the collagen from different 
treatments. +BD: Below detection. Data are presented as mean ± SD. 
IFN
P<0.0009 P<0.0009 P<0.00017 
(A) 25 Naive 
20 Naive-PPD 
Vaccinated 
15 
Vaccinated-PPD 
10 
 
5 
+BD +BD +BD 
0 
(B) 
200 
IL-10 Naive 
150 
Naive-PPD 
Vaccinated 
100 Vaccinated-PPD 
 
50 
 
 
0 
p
g
/m
L
 
p
g
/m
L
 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Cytokine levels in antigen stimulated peripheral blood mononuclear cells. A – 
IFN- is only detected in in stimulated PBMC from vaccinated calves. B – There are no 
differences in IL-10 in antigen stimulated PBMC from vaccinated or unvaccinated calves. 
ConA and medium were used as positive and negative controls (respectively). *BD: below 
detection. Due to experimental group size (n=2/group), statistical analysis could not be 
performed. 
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Abstract 
 
Johne’s disease is a chronic granulomatous enteritis of ruminants caused by 
Mycobacterium avium subsp. paratuberculosis (MAP) that results in significant economic 
losses for the cattle industry annually. Despite current limitations, vaccination holds future 
potential to effectively control and eliminate MAP infection. Therefore, the development of 
new vaccines with improved protection is currently an active area of research. One obstacle 
in the development of new vaccines is the difficulty in testing vaccine candidates. Bovine 
vaccine studies are difficult due to the long incubation period following infection causing 
these investigations to be lengthy and expensive. A long-term goal of our laboratory is to 
develop a simple, cost-effective method to specifically evaluate the host immune response to 
MAP to streamline the vaccine development process.  The current study investigated the in 
vivo, cell-mediated immune (CMI) response to MAP antigen using a subcutaneous implant 
device designed previously by our laboratory. The eight-week, longitudinal study evaluated 
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the implant device’s ability to collect immune responses in vivo in a population of MAP- 
immunized and naïve calves. The implants contained either collagen with saline only or 
collagen with MAP antigen, and cytokine (IFNand IL-10) levels within the implant were 
measured at 0, 2, 4, 6, and 8 weeks post-vaccination.  IFNand IL-10 production by 
peripheral blood leukocytes (PBL) collected from the calves was also assessed at these time 
points. PBL isolated from vaccinated calves and stimulated with MAP antigen had 
significantly increased production of IFNγ over those isolated from naïve calves beginning 2 
weeks post-vaccination and remained significantly increased throughout the study. No 
significant differences in IL-10 production by PBL were found.  IFNlevels in the MAP 
antigen-containing implants placed in vaccinated calves were significantly higher than the 
implants retrieved from naïve cattle at weeks 4 and 6 post-vaccination. These responses 
paralleled the responses observed in MAP-stimulated PBL from vaccinated calves. 
Significant differences between vaccinated and naïve calves in IL-10 levels within the 
implants were not observed.  The intradermal caudal fold test (CFT) demonstrated false- 
positive rates when one of our calves reacted to PPD-J prior to vaccination. Therefore, our 
implant device was capable of identifying each of the 3 vaccinated calves, suggesting 
increased specificity over the intradermal CFT.  Overall, the implant device consistently 
detects in vivo immune parameters and evidence shows this device may have a greater 
specificity than standard intradermal skin tests. 
 
 
Introduction 
 
Paratuberculosis is an enteric infection caused by Mycobacterium avium subspecies 
paratuberculosis (MAP) in cattle and other ruminant species [1]. Also known as Johne’s 
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disease, paratuberculosis causes a chronic granulomatous enteritis leading to persistent 
diarrhea and loss of body condition [2]. MAP infection has an estimated presence on 68% of 
US dairy farms with economic losses to the industry estimated at $200-$250 million yearly 
[3, 4]. The greatest financial loss to the dairy industry is decreased milk production; however, 
early culling rates and poor reproductive outcomes also play a large role [5]. Currently, there 
is no treatment for MAP infected animals and mechanisms of preventative control, such as 
biosecurity measures, herd management, and vaccination, are emphasized to mitigate 
economic losses [1, 6]. Initial infection occurs in calves via the fecal-oral route during the 
early neonatal period, and vertical transmission from cow to calf is considered the primary 
route of infection [7]. Calves are most susceptible to MAP infection the first few days to 
months of life, and by one year of age, the risk for infection in adult cattle is low, indicating 
the host’s immune response develops some degree of age-related MAP resistance [1, 7, 8]. It 
is known that only 10-15% of MAP-exposed calves will develop clinical disease and chronic 
wasting after a long incubation period that is known to last between 2-7 years [1, 2, 9]. This 
prolonged incubation period is known as Stage 1; in this period of infection, clinical signs are 
not observed and bacterial shedding is not detected. An obstacle facing MAP control within 
herds is the inability to detect Stage I animals before advancement into later disease stages 
(Stage II-III) in which cattle begin to shed bacteria in their feces [1, 10]. Therefore, 
vaccination is being sought for control and eradication of MAP due to the difficulty in 
identifying MAP-infected animals. 
The first use of a MAP vaccine was described in 1926 using a live vaccine shown to 
decrease the severity of clinical disease [2]. Currently, three inactivated, whole-cell vaccine 
preparations (Mycopar®, Silirum®, and Guidiar®) are commercially available with 
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Mycopar® (Boehringer Ingelheim Vetmedica Inc.) being the only approved vaccine for 
MAP in the United States [11, 12]. Vaccination has been shown to be effective in decreasing 
fecal shedding and clinical disease [13].  Elimination of disease and economic benefit has 
been observed after 4-6 years of vaccination in previously infected, unvaccinated herds; this 
eradication of MAP infection was observed when vaccination was combined with other 
management and biosecurity techniques [14], Unfortunately, vaccination against MAP is not 
widespread to date due to some limitations of the current vaccines. Drawbacks to the 
currently available vaccines include: lack of complete protection from disease and fecal 
shedding, development of granulomas at the site of injection, and cross-reactivity with other 
mycobacterial species including M. bovis [11, 15]. 
Despite the current limitations, vaccination may still be the best way to effectively 
control or eliminate MAP infection in the future; development of new vaccines with greater 
protection is an active area of research.  For instance, current research shows that subunit 
vaccines may have fewer drawbacks than whole-cell vaccines, such as the absence of 
granuloma formation at injection sites [16-18]. Research is also being conducted on live- 
attenuated strains. Live-attenuated strains contain various mutations that allow for a strong 
response from both the innate and adaptive immune systems without active infection, clinical 
disease, or pathogen transmission [19]. 
One obstacle in the development of new vaccines is the difficulty in testing vaccine 
candidates. Bovine vaccine studies are difficult due to the long incubation period following 
experimental infection which causes these investigations to be lengthy and expensive. As an 
alternative, cell culture and murine models have been used to study vaccine efficacy; 
however, these systems have not accurately predicted vaccine responses in the natural host 
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[8, 19].  An efficient and standardized natural host model is needed to quickly and effectively 
compare new vaccine candidates in vaccine trials across different laboratories. 
Evaluation of the host immune response, in particular the detection of cell-mediated 
immune (CMI) parameters, has been a critical component in regard to testing vaccines 
candidates. Numerous investigations evaluating the post-vaccination immune response to 
MAP have used parameters associated with the T-helper 1 (Th1) and CMI response, such as 
IFNlevels and intradermal skin thickness [20-22]. The focus of this research project is 
directed toward investigating the in vivo, CMI response of vaccinated and naïve cattle using a 
previously developed subcutaneous implant device.  Prior work in our laboratory included 
the development of a self-contained, removable device capable of subcutaneous implantation 
and collection of immunological parameters.  The purpose of the eight-week, longitudinal 
study reported here was to evaluate the implant device’s ability to collect immune responses 
to MAP antigen in vivo in a population of MAP-immunized and naïve calves. 
 
 
Materials and Methods 
 
Animals and vaccination 
 
Six Holstein bull calves were obtained by Laboratory Animal Resources at Iowa State 
University in Ames, Iowa. Calves weight approximately 250-300lbs and were housed in an 
outdoor research facility and divided randomly into the following two groups:  naïve (n=3) 
and MAP vaccinated (n=3). Calves were allowed to acclimate to their environment for one 
week prior to vaccination and initiation of the study. The three calves receiving 
immunization were vaccinated subcutaneously in the ventral neck region with Mycopar®, an 
inactivated, whole-cell vaccine (Boehringer Ingelheim Vetmedica, Inc., Saint Joseph, 
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Missouri), per the manufacturer’s instructions. Samples were collected from calves on day 0 
and weeks 2, 4, 6, and 8 post-vaccination. All animal protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) at Iowa State University (Ames, IA, 
USA). 
 
 
Implant device, collagen, MAP antigen 
 
For each time point, 12 stainless steel implant devices (described in detail in Chapter 
 
2) with 30um mesh inserts were autoclaved and loaded with PureCol® EZ Gel (Advanced 
BioMatrix, San Diego, CA). PureCol® EZ Gel is a commercially available, pre-formulated, 
purified Type I bovine collagen at 5mg/ml concentration that forms a firm gel at 37C. The 
collagen contains CMEM/F-12 medium with L-glutamine and L-alanine-L-glutamine. 
PureCol® EZ Gel (hereafter referred to as collagen) was stored at 4C in liquid form. A 
commercial preparation Mycobacterium paratuberculosis purified protein derivative johnin 
(PPD-J) intradermic tuberculin (NVSL, Ames, IA, USA) was used for this study and stored 
at 4C. PPD-J is a solution of phenolized phosphate buffer and tuberculoprotein at a 
concentration of 1.0mg/ml. Prior to implantation, PureCol® EZ Gel containing 30% PPD-J 
or sterile saline, as a control in separate implants, was loaded into the mesh lining within the 
cylinder of the implant. Implants were then placed at 37C for at least one hour allowing 
formation of a firm gel. 
 
 
Implantation procedure 
 
Using a halter and adjustable head gate, the six calves were restrained at day 0 for 
blood collection and implantation. The right and left lateral necks were sterilely prepped and 
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3ml of 10mg/ml lidocaine was dispersed into a localized area of approximately 4cm by 4cm. 
A 0.5cm incision was made via scalpel blade followed by insertion of the full implant using 
the implantation device. The implant was completely placed into the subcutis. A single 
interrupted suture was then placed to close the incision. Two implants were placed in each 
animal on opposite sides of the neck; the first, a control implant, containing collagen and 
saline and a second implant containing collagen and PPD-J. Ten milliliters of whole blood 
was collected in acid citrate dextrose via jugular venipuncture. After 48 hours, the calves 
were restrained for removal of the implant device. A single interrupted suture was placed in 
the skin to close each implant site after implant removal. The implantation, blood collection, 
and implant retrieval was repeated at 2, 4, 6, and 8 weeks. After transportation back to the 
laboratory, the nylon mesh and associated collagen plug were removed from the stainless-
steel housing of each implant. The collagen was then removed from the nylon mesh lining. 
For histopathology, an approximately 1mm x 4mm section of collagen was placed in 10% 
neutral buffered formalin and processed routinely for hematoxylin and eosin (H&E) 
staining. For cytokine analysis, the remaining collagen was cooled on ice and minced with 
100ul of complete RPMI media (cRPMI, Life Technologies, Grand Island, NY, USA). The 
supernatant was then collected and stored at -20C for future cytokine analysis (n=3 implants 
per group, vaccinated and naïve, per time point). 
 
 
Blood collection and cell culture 
 
At each time point, six blood samples were collected from naïve (n=3) and MAP-vaccinated 
(n=3) calves. Twenty milliliters of whole blood was collected in EDTA via jugular 
venipuncture. Ten milliliters of the EDTA-treated whole blood was placed in a 50 milliliter 
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conical tube with 40 milliliters of ACK Lysing Buffer at room temperature for 5-10 minutes. 
Leukocytes were then collected by centrifugation at 1000g for 10 minutes. The cell pellet 
was washed twice with phosphate buffered saline (PBS) and cells were then collected by 
centrifugation at 1000 g for 8 minutes. The peripheral blood leukocytes (PBL) were then 
suspended in cRPMI to achieve a final concentration of 5x10
6 
cells/well. Cells were plated in 
a 96-well plate and stimulated with Concanavalin A (Sigma-Aldrich, St. Louis, MO, USA) at 
2ug/ml, PPD-J (National Veterinary Services Laboratory, Ames, IA, USA) at 10ug/ml, or 
cRPMI medium for 24 hours at 37C and 5% CO2. The plate was spun at 300g for 5 minutes 
and supernatants were collected and placed at -20C for future cytokine analysis. 
 
 
Cytokine analysis 
 
Supernatants from the implant collagen as well as the PPD-J and Concanavalin A- 
stimulated PBL were incubated with magnetic beads in a 96-well plate at room temperature 
for two hours. Magnetic beads (MC10062-01, MC10026-01, Bio-Rad Laboratories Inc., 
Hercules, CA, USA) were pre-conjugated with IL-10 and IFN-capture antibody 
(MCA2110, MCA2112, Bio-Rad). Biotin-labeled IL-10 and IFN-detection antibodies 
(MCA1783B, MCA2111B, Bio-Rad) were added and incubated for one hour followed by a 
30 minute incubation with eBioscience
TM 
Streptavidin PE (Invitrogen, Thermo Fisher 
 
Scientific Inc., USA). The mean fluorescence intensity and bead classification was 
determined via Bio-Plex®200 reader (Bio-Rad) and compared to a standard curve to derive 
cytokine concentrations of each individual sample.  The following proteins were used to 
create a standard curve: recombinant bovine IFN-and recombinant bovine IL-10 
(PBP007A, PBP016A, Bio-Rad). Samples were analyzed in two different batches, and 
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therefore calculated with two different standard curves; the 0 and 2 week time points were 
analyzed together and time points 4, 6, and 8 weeks were analyzed together. For analysis, IL- 
10 and IFNlevels from PBL stimulated with media were subtracted from levels obtained 
from stimulated PBL from the same animal at the same time point. 
 
 
Caudal fold test (CFT) 
 
The caudal tail fold skin test was performed at the 0 week and 8 week time points as a 
tool to compare an established in vivo CMI response to the immune response of the implant 
in vaccinated calves.  Calves were injected intradermally in the left (0 week) and right (8 
week) tail fold with 0.1 ml of 1 mg/ml PPD-J and skin thickness is measured 72 hours post- 
injection. The skin thickness at week 0 and week 8 time points were measured via calipers; 
week 0 thickness was removed from week 8 thickness showing the overall change in 
thickness between vaccinated and naïve calves. 
 
 
Graphs and data analysis 
 
Graphs were made using GraphPad Prism 7 (La Jolla, CA). All data are shown as 
mean + standard error of the mean (SEM), and data sets were analyzed utilizing NCSS 12 
Statistical Software (NCSS, LLC, Kaysville, Utah). Normality tests (D’Agostino-Pearson 
omnibus normality test) were performed on the datasets, and in some instances, the data did 
not have a normal distribution; therefore, nonparametric tests were used for all analyses. 
Cytokine levels were compared between vaccinated and naïve calves using Friedman test for 
repeated measures followed by Dunn’s test for multiple comparisons. Skin test 
measurements were compared using Mann-Whitney test for unpaired data to compare ranks. 
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Results 
 
Cytokine production in antigen stimulated PBL 
 
Vaccination with Mycopar® showed significantly higher IFNproduction in PBL 
stimulated with the MAP antigen, PPD-J. IFNproduction by PBL isolated from vaccinated 
calves was elevated beginning 2 weeks post-vaccination compared with naïve controls and 
remained elevated throughout the 8 weeks of the investigation (Fig 1A). IFNlevels peaked at 
week 4 post-vaccination, and gradually declined over the remainder of the study (Fig 1A). 
Stimulation of PBL with PPD-J resulted in greater IFNproduction than Con-A in vaccinated 
calves (data not shown).  IL-10 levels were measurable at each time point throughout the 
study; however, significant concentration differences between naïve and vaccinated calves 
were not observed (Fig. 1B). 
 
 
Cytokine production in implants 
 
Levels of IFNwithin implants from calves vaccinated with Mycopar® were higher 
than those from naïve cattle beginning at week 2 post-vaccination. IFNwas highest in 
vaccinated calves at the week 4 time point, and was significantly elevated over naïve controls 
(P < 0.005, Figure 2A).  IFNlevels in implants from vaccinated animals remained 
significantly (P < 0.05) elevated over naïve animals at week 6, before declining at week 8 
(Figure 2A).   There were no significant differences between vaccinated and naïve calves in 
IL-10 levels within the implants at any time point in the study (Figure 2B). 
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Temporal cytokine responses post-vaccination 
 
Figure 3 compares the mean IFNconcentration for PPD-J stimulated PBL and the 
implants containing PPD-J in calves vaccinated with Mycopar® over time.  The in vivo pro- 
inflammatory cytokine response to MAP antigen paralleled the in vitro response, as 
evidenced by the similar temporal increase in IFNγ levels within the PPD-J-containing 
implants and those produced by PPD-J stimulated PBL collected from the same calves at the 
same time points. IFNγ production was maximal at week 4 post-vaccination for both PBL 
and implants; levels then declined gradually over the remainder of the study period. Naïve 
cattle had negligible IFNγ production by PBL in response to PPD-J and within the PPD-J 
containing implants (data not shown). 
 
 
Caudal fold skin test 
 
We used the PPD-J caudal fold test (CFT) to compare the implant response to a 
standard CMI test. Figure 4 shows the results before vaccination and at the 8 week time 
point. One calf exhibited increased thickness (10mm) at the CFT site before vaccination and 
thickness (10mm) in this calf at the 8 week time point remained the same. The remaining 2 
calves demonstrated 75% and 81% increases in skin fold thickness after vaccination 
compared to the naïve group which had only a 7% average increase in skin fold thickness. 
 
 
Discussion 
 
MAP vaccination studies have generally shown the induction of a CMI response post 
vaccination that contributes to reduced fecal shedding and clinical disease in ruminants [12, 
16, 17, 23-25]. Unfortunately, current vaccination strategies do not prevent infection or 
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transmission [11, 26, 27]. However, current subunit vaccine and attenuated vaccine 
candidates show potential as future immunizations that will protect against disease, eliminate 
fecal shedding, and prevent injection site granuloma formation [8, 16-18, 23, 28, 29]. To 
better evaluate these new vaccine candidates, a more efficient, predictive model for screening 
vaccine candidates is needed to assess protection in a natural host model. The rationale for 
this study was that measuring immune responses from within the animal will have benefit 
over ex vivo stimulated leukocytes and skin testing where cross reactivity with 
nonpathogenic mycobacteria is a current problem. The purpose of this longitudinal study was 
to expand on our laboratory’s prior development of a self-contained, removable device 
capable of subcutaneous implantation and collection of immunological parameters.  In this 
study, we were able to measure IFNwithin the implant collagen to identify which calves had 
received immunization. Our results showed the implants’ ability to consistently and 
significantly detect MAP-specific IFNresponses in vaccinated calves. These results are 
consistent with the IFNlevels observed in human intradermal DTH site investigations. Chu 
et al. used immunohistochemical stains in DTH sites after BCG vaccination and found that 
33% of cells (CD3+ T cells) at the DTH site contained IFN[30]. Previously, our lab detected 
an elevation in IFNwhen placing collagen and MAP into the subcutaneous tissues of calves 
compared to control sites consisting of collagen without MAP antigen [31]. 
This longitudinal study provided the opportunity to evaluate our implant’s ability to 
measure cytokines at multiple time points post-vaccination. IFNlevels at the 4 and 6 week 
time points were significantly greater in vaccinated compared to naïve calves. In contrast, the 
IL-10 measured within the collagen did not reveal any significant patterns to facilitate the 
identification of successful immune protection after MAP vaccination. Within peripheral 
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blood leukocytes, IL-10 demonstrated a small peak across all experimental groups at week 6 
(45 days). This has been demonstrated in prior research by Stabel et al. in which IL-10 in 
MPS-simulated cultures was upregulated between 7 and 90 days in calves vaccinated against 
MAP. The significance of this IL-10 elevation is unknown; however, it may have 
implications in the development of the immune response of cattle in the period immediately 
following vaccination. 
Figure 3 shows the correlation between the implants’ IFNresponse and the response by 
the stimulated PBL. The graphs show that only the vaccinated calves stimulated with MAP 
antigen, either in cell culture or subcutaneously placed implants, exhibited detectable levels 
of IFN. The PPD-J stimulated leukocytes (red) and PPD-J containing implant (green) had 
similar patterns responses in vaccinated and naive cattle. This pattern of IFNresponse is 
similar to research investigating the CMI response at the known sites of MAP infection such 
as the ileum and lymph nodes. Coussens et al. revealed a greater expression of pro- 
inflammatory cytokines including IFNwithin the ileal tissues of infected cattle compared to 
naïve cattle. Systemic evaluation of cytokines is a well-researched topic in which cytokine 
profiles from stimulated PBMC cultures have demonstrated greater levels of IFNafter 
immunization against and infection with MAP in ruminants [32-37]. Stabel et al. investigated 
the effects of immunization after vaccination with the killed, commercially, available 
vaccine, Mycopar® [22]. CMI parameters explored in this study included MAP-specific 
IFNlevels in response to PPD-J as well as the intradermal comparative cervical skin test. 
Seven days after vaccination, strong IFNresponses were measured and lasted until the 
study’s completion at twelve months [22]. Similarly high concentrations of IFNwere noted 
in other laboratories such as the long-term study of Mycopar®-vaccinated, Dutch dairy cows 
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by Muskens et al. In this study, high levels of IFNwere observed throughout the two year 
period following vaccination in comparison to naïve, control cows [38]. 
The caudal fold test is a widely used diagnostic tool for detection of bovine 
tuberculosis and has shown good specificity when used as a diagnostic tool for MAP 
infection [2, 39, 40]. Monoghan et al. demonstrates the increase of IFNto correlate to an 
increase in skin thickness of the comparative skin test [21]. Stabel et al. also evaluated skin 
thickness after intradermal injection with PPD-M. avium and PPD-M. bovis; these results 
showed that immunized calves had a stronger reaction to PPD-M. avium compared to PPD- 
M. bovis; one calf was minimally and falsely reactive to PPD-M. bovis suggesting that 20% 
of the cattle in this study would be falsely diagnosed with MAP-infection [22]. We found 
similar false-positive rates in our vaccination study in which one of our calved reacted to 
PPD-J prior to vaccination. In our study, the skin thicknesses at week 0 and week 8 time 
points were measured. A significant difference between naïve and vaccinated cattle was not 
observed, likely due in part to one calf having a large thickness prior to and following 
vaccination. This is not an uncommon observation regarding intradermal mycobacterial 
testing due to cross-reactivity of environmental mycobacteria [22, 41-43]. The remaining 2 
calves demonstrated 75% and 81% increases in skin fold thickness after vaccination 
compared to the naïve group which had only a 7% average increase in skin fold thickness. It 
is interesting that our implant was able to identify this calf as vaccinated, which may suggest 
increased specificity over the skin test. 
Measuring cytokine expression profiles in PBLs and tissue samples provide beneficial 
information on mycobacterial immune responses and diagnostic markers at the systemic and 
gastrointestinal level. However, these evaluation methods are costly and require extensive 
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time in performing in vitro assays that may not indicate a protective response in vivo. 
Currently, minimal literature exists on the immune response at the level of the DTH site in 
cattle. This implant device demonstrated reproducible and significant measurements of 
IFN for detection of cell-mediated immunity and vaccination in cattle. This method for in 
vivo immune detection has the potential to provide a better understanding of the MAP 
vaccination-induced immune response by mimicking a  
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Figure 1.  Leukocytes were collected from naïve and vaccinated calves at two-week intervals 
post-vaccination and were stimulated with MAP antigen, and cytokine production was 
measured via multiplex bead assay.  A) IFNγ production secondary to stimulation with MAP 
antigen was significantly higher in vaccinated compared to naïve calves beginning at 2 weeks 
post-vaccination, and remained significantly higher throughout the study.  B) IL-10 
production following stimulation with MAP antigen was not significantly different between 
vaccinated and naïve calves (*, P < 0.05, Friedman test for repeated measures and Dunn’s 
test for multiple comparisons). 
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Figure 2.  Implants containing collagen infused with MAP antigen (PPDJ) were placed 
subcutaneously in naïve and vaccinated calves for 48 hrs every two weeks following 
vaccination to capture immune responses.  Cytokine levels within the implants were 
measured following removal via multiplex bead assay. A) IFNγ levels within the implants 
were significantly higher in vaccinated calves at 4 and 6 weeks post-vaccination.  B) IL-10 
levels within the implants were not significantly different between naïve and vaccinated 
calves at any time point (*, P < 0.05; **, P < 0.005, Friedman test for repeated measures and 
Dunn’s test for multiple comparisons). 
69 
 
 
 
 
 
 
 
Figure 3.  Comparison of IFNγ levels over time in calves vaccinated with Mycopar®. 
Temporal production of IFNγ in calves post-vaccination was assessed in both peripheral 
blood leukocytes (PBL) stimulated with MAP antigen and subcutaneous implants containing 
collagen infused with MAP antigen.  IFNγ production by PBL paralleled the levels isolated 
from the implants in vivo, with the maximal response noted 4 weeks post-vaccination. 
Naïve cattle had negligible IFNγ production by PBL in response to MAP antigen and within 
the MAP-antigen containing implants (data not shown). 
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Figure 4.  The PPD-J caudal fold test (CFT) was used as a standard established assessor of 
the cell-mediated immune response to Mycopar® vaccination.  The increase in skin thickness 
at 8 weeks post-vaccination was recorded for each calf in the study.  Calves that received the 
vaccine tended to have an increase in skin fold thickness compared to unvaccinated calves; 
however, one calf that received the vaccine had increased thickness at the vaccine site prior 
to vaccination. 
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Abstract 
 
Mycobacterium avium subsp. paratuberculosis (MAP) is the causative agent of Johne’s 
disease, a chronic, infectious disease of cattle and other ruminants.  MAP infection results in 
a slow and progressive enteric disease that leads to large economic losses in the dairy 
industry each year. Due the difficulty in identifying subclinical animals, vaccination 
programs may contain the greatest potential for control and elimination of MAP-infection in 
ruminants. The research in this project will build on a previously designed subcutaneous 
implant device capable of in vivo CMI collection of immune parameters; our investigation 
explored the device’s potential as a bacterial killing assay. Collagen and MAP-containing 
implant devices (6 per animal) were placed in the subcutaneous tissues of calves divided into 
two groups, naïve (n=3) and Mycopar® vaccinated (n=3) at 14 and 20 days post-vaccination. 
After 5 days, implants were retrieved from the subcutaneous tissues and collagen was 
processed for evaluation of IFNcytokine levels and flow cytometric analysis of bacterial 
viability. Three weeks post-vaccination, flow cytometric analysis of the bacteria retrieved 
from collagen demonstrated a significantly greater percentage of propidium iodide (PI) 
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stained-MAP in the vaccinated calves compared to naïve calves, indicating enhanced bacteria 
killing within the vaccinated calves. Collagen from vaccinated calves at the three week time 
point also demonstrated a significantly higher production of IFN than collagen from naïve 
calves.  By exploring the implant device’s ability to assess bacterial viability with flow 
cytometry, this investigation demonstrated the potential for the device’s use as a bacterial 
challenge model to efficiently and economically screen novel vaccine candidates in a natural 
host model. 
 
 
Introduction 
 
Paratuberculosis is a chronic, infectious disease of cattle and other ruminants caused by 
Mycobacterium avium subsp. paratuberculosis (MAP). MAP infection results in a slow and 
progressive enteric disease that leads to the clinical symptoms widely known as Johne’s 
disease [1-3]. Due to a reduction of milk production and early culling of sick cattle, MAP 
infection is recognized as a major herd problem in the dairy cattle industry. Economic losses 
to the United States dairy industry are estimated between $200-250 million per year [4-6]. 
Various methods of prevention and control are currently emphasized such as improvement 
of biosecurity methods, test-and-cull management strategies, and vaccination programs [2, 
7]. The largest obstacle to elimination of MAP infection is the difficulty in identifying MAP- 
infected cattle in the early stages of disease in which clinical symptoms are absent and MAP 
bacteria are shed into the environment [8, 9]. It is widely known that primary transmission 
occurs via fecal-oral transmission in the neonatal period; however, only a small percent of 
exposed cattle will develop chronic wasting disease after the 2-7 year latent period observed 
after transmission [2, 3, 9-11]. Due to this difficulty in identifying subclinical animals, 
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vaccination programs may contain the greatest potential for control and elimination of MAP- 
infection in ruminants. 
Commercially available MAP vaccines are unable to provide full immune protection 
from MAP infection. These vaccines have been shown to reduce fecal shedding and delay 
clinical disease progression; however, vaccination does not prevent fecal shedding or disease 
transmission [12, 13].  Although vaccine strain development is an active area of research in 
the MAP world, a crucial need exists for a new method to efficiently and economically 
screen novel vaccine candidates. One of the largest obstacles in the development of new 
vaccines is the poor correlation between initial screening tests and secondary evaluation 
methods in the sheep and cattle natural host models. For instance, cell culture models and 
murine models have been used as initial vaccine screening tests, but do not reliably predict 
the vaccine response in a natural host model [10, 14, 15]. Previous investigations in our 
laboratory included work toward the development of an initial vaccine screening test for use 
in the natural bovine host model. In prior studies we used a self-contained, removable device 
capable of collecting immune parameters and measuring in vivo cell-mediated immunity 
(CMI) in the subcutaneous tissue of cattle. The implant device was able to successfully 
identify vaccinated vs naïve calves between 2 and 8 weeks post-vaccination. The research 
proposed here will use our subcutaneous implant as a platform for a bacterial killing assay in 
vaccinated calves. 
A wide variety of bacterial challenge models and assays are currently used in 
paratuberculosis research. Post-vaccination challenge models explore the response of the 
immune system and its ability to eliminate pathogens and avoid disease. For instance, 
common assessment methods, due to their cost-effective nature, are in vitro assays such as 
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survival rates in infected bovine cultured macrophages [16, 17]. Kabara et al. performed a 
macrophage culture study to demonstrate that populations of MAP-infected macrophages 
contain fewer apoptotic cells than control cells, and that MAP infection reduces the 
sensitivity of infected macrophages to induction of apoptosis by H2O2 [16]. In addition, 
various oral and inoculation challenge models exist in numerous species including mice, 
sheep, goats, and cattle. Unfortunately, this lack of a standardized challenge model makes 
comparison of new vaccine candidates across different laboratories highly challenging [18]. 
However, recent advancements toward standardizing animal challenge models and vaccine 
trials for MAP have been implemented. Supported by the Johne’s Disease Integrated Project 
(JDIP), a committee of MAP researchers was formed called the JDPI Animal Model 
Standardization Committee (AMSC). Committee members formulated guidelines and 
specific parameters for each MAP host model [19]. In a paper by Bannantine et al. evaluating 
22 vaccine candidates, a 3-phase investigation was implemented using the standardized 
testing parameters [10, 14]. Phase 1 evaluated survival in bovine macrophages and Phase II 
used the murine model to evaluate the bacterial load in tissues at varying time points after 
MAP challenge. Finally, Phase III was conducted in goat kids [14, 18]. The results of the 
study indicated that the use of the 3-phase, macrophage to mouse to ruminant platform may 
need adjustments, particularly in the macrophage and mouse models where evidence of 
attenuation in vitro and within an unnatural host, respectively, does not appear to predict 
natural host protection [14, 17, 18]. 
Another post-vaccination challenge model is the use of in vitro and in vivo bacterial 
killing assays to examine the influence of vaccination on the immune system’s ability to kill 
MAP organisms.  Post-vaccination screening assays to detect bacterial death or clearance 
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serve as biomarkers for immunocompetence to immunization. A wide variety of bacterial 
viability techniques are used in research including culture based techniques, cell integrity 
assessments, sequencing approaches, measurements of RNA, DNA, RT-PCR and qPCR , 
ATP detection, isotype probing, and membrane integrity assessment with selective stains 
[20]. For this experiment, staining for membrane integrity was chosen to assess MAP 
viability within the retrieved collagen implants. Propidium iodide (PI) is a red-fluorescent 
dye that permeates compromised cell membranes and binds to internal nucleic acids.  PI 
staining is a widely used technique for rapid enumeration of dead bacteria. Lahiri et al. has 
demonstrated the success of PI in assessing the membrane integrity of Mycobacterium 
leprae in a murine study [21].  A second study by Hendon-Dunn et al. used flow cytometry 
to visualize fluorescently labeled bacteria [22]. The use of flow cytometry to assess PI 
stained bacteria allows researchers to gate and enumerate the number of dead bacteria. [22- 
25]. The research in this project will build on a previously designed subcutaneous, in vivo 
CMI collection device; our investigation will explore the device’s potential as a bacterial 
killing assay. A subcutaneous bacterial challenge model could prove to be an efficient and 
cost-effective method for screening novel vaccine candidates in a natural host model. 
 
 
Materials and Methods 
 
Animals and vaccination 
 
Four to six-week-old castrated Holstein bull calves were obtained by Laboratory 
Animal Resources at Iowa State University in Ames, Iowa and housed in an outdoor research 
facility for two weeks. Calves were divided randomly into two groups, naïve (n=3) and 
vaccinated (n=3) and allowed to acclimate for three days prior to vaccination. Three calves 
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received immunization and were vaccinated subcutaneously in the ventral neck region with 
Mycopar®, an inactivated, whole-cell vaccine preparation made by Boehringer Ingelheim 
Vetmedica, Inc., Saint Joseph, Missouri), per the manufacturer’s instructions. Fourteen days 
post-vaccination, calves were moved to isolation housing at the Iowa State University 
College of Veterinary Medicine Livestock Infectious Disease Isolation Facility (Ames, IA). 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC) at Iowa State University (Ames, IA). 
 
 
Bacterial inoculum 
 
The MAP strain K10 was obtained from Dr. John Bannatine with the United States 
Department of Agriculture (USDA) Agriculture Research Service (ARS) in Ames, Iowa. The 
bacterial culture was maintained in Middlebrook 7H9 broth supplemented with mycobactin J. 
Bacterial concentration was determined by measuring absorbance at 540nm in comparison to 
a standard curve of MAP optical density at 540nm. Bacteria were then adjusted to a final 
concentration of 3.3 X 10
7 
CFU/mL and suspended in our collagen, Matrigel®. The MAP 
K10 used in this project demonstrated greater than 90% viability prior to resuspension into 
Matrigel® collagen. 
 
 
Implant, collagen, and experimental procedure 
 
At two time points post-vaccination, 14 and 20 days, calves were implanted with 
collagen and MAP-containing steel implants. Thirty-six implant devices (described in detail 
in Chapter 2) were autoclaved and loaded with Matrigel® Matrix (Corning Life Sciences, 
Tweksbury, MA) and MAP. Matrigel® Matrix is a commercially available, solubilized 
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basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma, a tumor with multiple extracellular matrix proteins, including laminin, collagen IV, 
heparin sulfate proteoglycans, entactin/nidogen, and a number of growth factors. Matrigel® 
Matrix has a protein concentration of 8-12 mg/ml and forms a firm gel at room temperature. 
Prior to implantation on day 14 post-vaccination, Matrigel® Matrix containing 1 X 10
7 
CFU 
was loaded into the mesh lining within the cylinder of each implant. The bacterial load was 
increased for the second set of implants on day 20 post-vaccination; Matrigel® Matrix 
contained 1 X 10
8 
CFU per implant for this second group of implants. Implants were then 
placed at 37C for at least one hour. On day 14 post-vaccination, six calves were restrained for 
blood collection and implantation using a halter and adjustable head gate. The right and left 
lateral necks were sterilely prepped and 3ml of 10mg/ml lidocaine was dispersed into three 
localized areas on each side of the neck. A total of six implants (three implants per side) 
were placed in each calf. Approximately 0.5 cm incisions were made via scalpel blade 
followed by insertion of the full implants using the implantation device. Single interrupted 
sutures were placed to close the incisions. Ten milliliters of whole blood were collected in 
EDTA via jugular venipuncture. After 5 days, the calves were restrained for removal of the 
implant device, and a single interrupted suture was placed in the skin to close each implant 
site. The implantation and blood collection were repeated at day 20 post-vaccination. At day 
25 post-vaccination, calves were humanely euthanized for implant retrieval, collection of 
tissue surrounding implant, and collection of regional draining lymph node. 
After transportation back to the laboratory, the nylon mesh and associated collagen 
plug were removed from the stainless-steel housing of each implant. The collagen was then 
removed from the nylon mesh lining. Implants were halved for various future analyses 
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including: histopathology, cytokine analysis, and flow cytometry. In total, six implants were 
removed per calf and halved for various analyses. Per calf, three halves were formalin fixed 
for histopathologic examination, three halves were shared with collaborators for future RNA 
isolation and genetic sequencing, three halves were used for flow cytometric analysis and 
viability, and the remaining three halves were used for collection of cytokines (round 2 
implants) and duplicates for flow cytometric analysis (round 1 implants). 
For histopathology (n=9 per group per time point), a section of each implant, 
subcutaneous tissue surrounding implant, and regional lymph node tissue were placed in 
10% neutral buffered formalin and processed routinely for hematoxylin and eosin (H&E) and 
Ziehl–Neelsen acid-fast staining.  Immunohistochemical staining with the macrophage- 
specific calcium-binding protein, Iba-1, was used to assess for macrophagic infiltrate into the 
collagen sections. A granulomatous enteritis was used as a positive control. An antigen 
retrieval step using 10mM sodium citrate buffer of pH 6.0 was performed. Slides were then 
washed in 3% hydrogen peroxide and blocked with 3% bovine serum albumin and 0.05% 
Triton-X in tris-buffered saline. Four incubations followed:  Iba-1 (1:500 dilution, 16 
hours)(Abcam Inc., Cambridge, MA); ImmPRESS Horseradish Peroxidase (HRP) Polymer 
Reagent (per instructions, 30 minutes)(Vector Laboratories, Burlingame, CA); 
VECTOR NovaRED Peroxidase (HRP) Substrate Kit (per instructions, 5 minutes) (Vector 
Laboratories); Hematoxylin Gill Sol. No 2 (1.5 minutes) (Sigma-Aldrich, St. Louis, MO). 
For cytokine analysis, a halved-implant section was cooled on ice and minced with 
100ul of complete RPMI media (cRPMI, Life Technologies, Grand Island, NY, USA). The 
supernatants were then collected and stored at -20C for future cytokine analysis (n=9 per 
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group, vaccinated and naïve, day 20 post-vaccination). For bacterial viability analysis, a 
section of collagen was processed (described in section 2.7) for flow cytometric analysis. 
 
 
Blood collection and cell culture 
 
Blood samples were collected from naïve (n=3) and MAP vaccinated (n=3) calves 
five days after implantation at each time point. Ten milliliters of whole blood was collected 
in EDTA via jugular venipuncture and placed in a 50 milliliter conical tube with 40 milliliters 
of ammonium-chloride-potassium (ACK) Lysing Buffer at room temperature for 5-10 
minutes. Leukocytes were then collected by centrifugation at 1000g for 10 minutes. The cell 
pellet was washed twice with phosphate buffered saline (PBS) and cells were then collected 
by centrifugation at 1000g for 8 minutes. The leukocytes were then suspended in cRPMI to 
achieve a final concentration of 5x10
6 
cells/well after gating out cells less than 6um and 
greater than 12um in diameter. Cells were plated in a 96-well plate and stimulated with 
Concanavalin A (Sigma-Aldrich, St. Louis, MO, USA) at 2ug/ml, purified protein derivative- 
johnin (PPD-J, National Veterinary Services Laboratory, Ames, IA, USA) at 10ug/ml, or 
cRPMI medium for 24 hours at 37C and 5% CO2. The plate was spun at 300g for 5 minutes 
and supernatants were collected and placed at -20C for future cytokine analysis. 
 
 
Cytokine analysis 
 
Supernatants from the implant collagen as well as the PPD-J and Concanavalin A- 
stimulated peripheral blood leukocytes (PBL) were incubated with magnetic beads in a 96- 
well plate at room temperature for two hours. Magnetic beads (MC10062-01, MC10026-01, 
Bio-Rad Laboratories Inc., Hercules, CA, USA) were pre-conjugated with IL-10 and IFN-
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capture antibody (MCA2110, MCA2112, Bio-Rad). Biotin-labeled IL-10 and IFN- detection 
antibodies (MCA1783B, MCA2111B, Bio-Rad) were added and incubated for one hour 
followed by a 30-minute incubation with eBioscience
TM 
Streptavidin PE (Invitrogen, 
Thermo Fisher Scientific Inc., USA). The mean fluorescence intensity and bead classification 
was determined via Bio-Plex®200 reader (Bio-Rad) and compared to a standard curve to 
derive cytokine concentrations of each individual sample. The following proteins were used 
to create a standard curve: recombinant bovine IFN-and recombinant bovine IL-10 
(PBP007A, PBP016A, Bio-Rad). 
 
 
Flow cytometry for viability 
 
Flow cytometry was performed to assess bacterial viability on the retrieved collagen. 
 
A section of implant collagen was placed in 0.5ml radioimmunoprecipitation assay 
(RIPA) buffer (Thermo Fisher Scientific Inc., USA) for 10 minutes on ice. Samples were 
then vortexed for 30 seconds and any remaining large particles were removed using a 40 um 
cell strainer followed by 10ml of phosphate-buffered saline. Samples were centrifuged for 20 
min at 3000 rpm, and the pellet was suspended in 300ul of 0.9% saline. Cells were then 
incubated at room temperature for 20 minutes with 0.2 ug/ml fluorescein diacetate (FDA). 
Propidium iodide (PI) was added to the samples at a concentration of 2 ug/ml and samples 
were run using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) and analyzed 
with FlowJo V10 software (Tree Star, Inc. San Carlos, CA). 
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Caudal tail-fold skin test 
 
The caudal tail fold skin test was performed at the end of the study. Calves were 
injected intradermally in the right tail fold with 0.1 ml of 1 mg/ml PPD-J and skin thickness 
was measured 72 hours post-injection. 
 
 
Graphs and analysis 
 
Graphs were made using GraphPad Prism 7 (La Jolla, CA). All data are shown as 
mean +/- standard error of the mean (SEM). Normality tests (D’Agostino-Pearson omnibus 
normality test or Shapiro-Wilk normality test) were performed on the datasets, and in some 
instances, the data did not have a normal distribution; therefore, nonparametric tests were 
used for some analyses. Differences between MAP viability (Fig. 1, 2), IFNγ levels (Fig. 3), 
and skin test thickness (Figure 5) from retrieved collagen was assessed using a non- 
parametric Mann-Whitney test. IFNlevels measured from stimulated peripheral blood 
leukocytes (Fig. 4A, B) were assessed using a Kruskal-Wallis test for multiple comparisons. 
 
 
Results 
 
Flow cytometric analysis of bacterial viability 
 
Immunologic responses to vaccination were characterized by flow cytometric 
analyses of bacterial viability. Figure 1 and 2, A-D show how the gate for dead bacteria (PI+) 
was established and Figure 1 and 2, E-G demonstrate the differences, if observed, between 
the vaccinated and naïve group.  Although FDA staining was performed, interference with 
the Matrigel® caused a spill-over signal into the PI+ channel; therefore, an accurate FDA+ 
bacterial population could not be determined and comparison of bacterial viability was 
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assessed between naïve and vaccinated groups by total PI+ bacteria. Fourteen days post- 
vaccination (Fig. 1), the collagen implanted for 5 days (implanted on day 14, retrieved on day 
19) did not demonstrate significant differences in PI+ MAP between naïve and vaccinated 
calves. The second group of implants (implanted day 20 and removed on day 25) shown in 
Figure 2 showed that the collagen retrieved from calves in the third week after vaccination 
demonstrated a significantly greater percentage of PI+ (dead) bacteria. In this second group 
of implants, the initial number of live bacteria was higher at 1x10
8 
CFU/ml. 
 
IFNfrom implants and stimulated peripheral blood leukocytes 
 
Vaccination with Mycopar® resulted in significantly higher (P = 0.0022) IFN production 
from the collagen retrieved from vaccinated calves during the third week (day 20-25) post-
vaccination (Fig. 3). Cytokine levels were not assessed at the 2 week time point as the 
collagen was used for other analyses. IFNlevels were measured in the supernatants of 
stimulated PBL (Fig. 4); concentrations of IFNfrom cells cultured in medium alone were 
subtracted from cells stimulated with the positive control, ConA, and PPD-J before analysis. 
Statistically significant differences were not observed between the ConA and PPD-J 
stimulated leukocytes of vaccinated and naïve calves. While trends were present for 
IFNbetween vaccinates and naïve calves, statistical significance was not achieved. 
 
 
Caudal tail-fold test 
 
As a second measure of cell-mediated immunity, the caudal tail-fold test with PPD-J 
was performed and skin thickness between the vaccinated and naïve groups was assessed 
(Fig 5, Table 1). Statistical differences were not observed between vaccinated and naïve 
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cattle; however, an overall trend was observed in which the vaccinated calves had skin 
thickness measurements 10mm compared to the naïve group with measurements of 5mm. 
 
 
Histopathology 
 
All implant sections were processed and stained with H&E and Ziehl-Neelsen acid- 
fast staining. Figure 6A, B show H&E sections at 10x with 40x insets; overall, a trend toward 
higher cellularity within the collagen retrieved from vaccinated calves was observed during 
the second week post vaccination.  A trend in immune cell infiltrate cellularity was not 
observed in the sections from the implants collected from the third week post-vaccination. In 
all groups, the majority of cells are degenerate neutrophils with lesser numbers of 
macrophages and lymphocytes Figure 6C, D shows acid-fast staining of collagen sections 
from naïve and vaccinated calves. A trend in the amount of bacteria was not observed, and 
MAP was observed intracellularly within both groups of calves.  Immunohistochemical 
staining with the macrophage-specific calcium-binding protein, Iba-1, was used to assess for 
macrophagic infiltrate into the collagen sections and a positive control is observed in Figure 
6E. Rare Iba-1 positive cells were found in the collagen of vaccinated calves (Fig. 6F), but 
not noted in the collagen sections retrieved from naïve calves (Fig. 6G). 
At the study’s completion, the tissue surrounding an implant as well as a prescapular 
lymph node was collected in each calf for histological analysis. Figure 7A-C show increasing 
magnification of the H &E stained subcutaneous tissue surrounding the previously placed 
implant. Red asterisks illustrate the space that was occupied by the implant. The H&E stains 
reveal a marked inflammatory response comprised of numerous macrophages and degenerate 
neutrophils with low numbers of lymphocytes. This inflammatory response is greatest in the 
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area directly surrounding the implant; inflammation appears to decrease with distance from 
the implant. A Ziehl-Neelsen acid-fast stain was performed on the subcutaneous tissue and 
Figure 7D, E show intracellular and extracellular bacteria within the tissues surrounding the 
implant. Overall, low numbers of MAP were observed in the subcutaneous tissues of some 
calves and appeared independent of vaccination status. Finally, Figure 8 shows the 40x 
magnification of acid-fast stained prescapular lymph node sections in naïve (Fig. 8A) and 
vaccinated (Fig. 8B) calves.  Low numbers of MAP were observed in the prescapular lymph 
nodes of some calves and appeared independent of vaccination status. 
 
 
Discussion 
 
Vaccination programs used in the dairy cattle industry are primarily designed to 
prevent diseases that result in production losses and early culling [12]. Several existing 
bovine vaccines, including the available MAP vaccines, have been successful for controlling 
or reducing many infectious diseases in herds [15, 26, 27]. Advantages to MAP vaccination 
include reduction in numbers of clinical stage animals and decreased fecal shedding of 
bacteria [15, 28-31]. It is well-known that commercially available vaccines do not eliminate 
fecal shedding, and therefore do not eradicate disease transmission in a dairy herd [10, 15, 
28-30]. Development of new vaccines against paratuberculosis is an area of active research 
with protein subunit, DNA, and attenuated-live vaccines being investigated as potential 
candidates [10, 12, 15]. The ideal vaccine for MAP infection would induce a sustained cell- 
mediated immune response that prevents bacterial shedding and disease progression [10]. In 
addition, an ideal vaccine candidate would not form an injection site granuloma that is 
currently observed following MAP vaccination [32-34]. A new vaccine with improved 
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protection could provide control and elimination of MAP infection in dairy herds; however, 
current vaccine research is slowed due to the extensive costs and lengthy time frame 
necessary for vaccine testing. The development of a rapid and economical vaccine screening 
method is needed to efficiently test novel vaccine candidates in natural host models. 
The primary goal of this study was to investigate a subcutaneous bacterial challenge 
model for use as an initial screening method of novel MAP vaccine candidates. The rationale 
behind this method is based on the inability of current screening methods, such as murine 
models and cell culture systems, to accurately predict the protective immunity in natural host 
models such as cattle, sheep, goats, and deer [10]. Use of a rapid and simple bacterial 
challenge model could substantially save time and costs involved in testing a vaccine strain 
that showed promise in a cell culture model but is not protective in the natural host. 
For this study’s purpose we chose a bovine host model and used the commercially 
available vaccine, Myopar®, to test our device’s ability to function as a bacterial killing 
assay. We demonstrated that vaccination with Mycopar® vaccine elicited a strong 
IFN response to MAP within the collagen when compared to naïve cattle. These findings 
are consistent with the findings observed in Chapters 2 & 3 in which vaccinated cattle 
consistently demonstrated an IFNresponse to the MAP antigen, PPD-J, compared to naïve 
calves. This suggests that the implants elicit reliable cytokine responses to MAP organism 
and MAP antigen. These results are also consistent with numerous studies detecting an 
increase in IFNand other Th1, pro-inflammatory cytokines within ileal and lymph node 
tissues of MAP infected cattle [35-38]. For instance, Lee et al. used immunohistochemistry 
and in situ hybridization techniques to demonstrate a similar increase of IFNexpression in 
the ileal tissues of clinically infected cattle that was not observed in nonclinical animals [37]. 
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It should also be noted that when compared to other standard methods of CMI 
detection, such as DTH caudal tail-fold skin testing and peripheral blood stimulation, the 
IFNresponse detected within the collagen was the only method to consistently find 
significant differences between vaccinated and naïve groups of cattle. In our study, 
differences were not observed between groups when comparing skin test thickness or 
IFN levels in peripheral blood stimulation. These findings are similar to the findings we 
observed in Chapter 2 in which one of the calves exhibited a strong response to the 
intradermal DTH test prior to MAP vaccination. Similar studies have been performed in 
which poor specificity of DTH tests were observed in vaccinated herds. Hines et al. 
evaluated the specificity of the johnin DTH skin test in MAP-vaccinated goats. The study 
used a caprine model to look at various immune parameters following vaccination with 5 
experimental, attenuated strains of MAP vaccine candidates compared to the commercial 
control vaccine, Silirum®. Intradermal skin testing was performed at various time points 
before and after vaccination using three types of PPD: PPD-M. avium, PPD-M.bovis, and 
PPD-johnin. The results from this study showed that the commercial vaccine, Silirum®, as 
well as some of the experimental vaccines, produced false-positive results with the all three 
PPD skin tests [39]. The low specificity observed with intradermal DTH testing is likely due 
to cross-reactions or previous sensitization of animals to environmental mycobacterial 
species. Many antigens are shared between mycobacteria, and non-specific responses are 
not uncommon observations [40]. 
Flow cytometry using propidium iodide (PI) staining was used to enumerate 
percentage of dead bacteria from total bacteria. The host response to the bacteria-containing 
collagen revealed no significant differences in vaccinated and naïve cattle at the two week 
post-vaccination time point. Percentages of dead bacteria at this time point were low and 
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ranged between 2-9% of total bacteria within the implant. However, flow cytometric analysis 
of bacterial viability at three weeks post-vaccination did comprise a significantly greater 
percentage of PI+ bacteria with an average percentage of dead bacteria of 29.5% and 44.6% 
in naïve and vaccinated cattle, respectively. These results indicate that vaccinated calves can 
be screened for vaccine-induced killing responses as early as 3 weeks post-vaccination. This 
finding parallels a longitudinal study by Stabel et al. that followed the host immune response 
for 1-year post-vaccination. In this study, IFNsecretion in PPD-J stimulated PBMCs were 
measured in vaccinated and control calves at day 0,7,14,30, 90, 180, 270, and 360; Stabel et 
al. showed a steady increase in IFNlevels after vaccination with a peak level of IFNat 30 
days post-vaccination. Stabel et al. also demonstrated a drop in IL-4 concentration secreted 
from stimulated PBMCs between 14 and 30 days post-vaccination. An increase in antibody 
was also observed after 14 days on an immunoblot of sera. These vaccine-induced 
immunological findings by Stabel et al. regarding stimulated PBMC IFNand IL-4 levels as 
well as antibody acquisition all occurred between day 14-30 post-vaccination; similarly, in 
the implant collagen described in Chapter 2, a peak in IFNconcentration was observed at 4 
weeks post-infection. It is hypothesized that the switch from low percentages of dead bacteria 
at 2 weeks post-vaccination to the greater levels observed at 3 weeks, may be correlated to 
these alterations in immune parameters observed between 14-30 days post-vaccination [26]. 
Furthermore, the first round of implants contained 1x10
7 
CFU/implant compared to the 
second round of implants that contained 1x10
8 
CFU/implants; it is possible the low bacterial 
load in the first round of implants was not large enough to mount a significant Th1 response 
in only 5 days. Future studies may benefit from an increased duration of implantation. 
The collagen implants retrieved from both calf groups contained an immune cell 
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infiltrate comprised morphologically of a large population of markedly degenerate 
neutrophils. Low numbers of macrophages and lymphocytes were noted. The first round of 
implants at 2 weeks post-vaccination exhibited a greater cellular density in vaccinated calves 
than observed in the collagen of naïve calves; however, this trend was not observed in the 
histological sections from the implants at 3 weeks post-vaccination. It is speculated that the 
loss of differences in cell density between the groups is attributed to the rapid re-implantation 
of the second group of implants only 24 hours after retrieval of the first implants; when the 
second round of implants were placed, the collagen-containing device was positioned into an 
environment with an immune response primed by the first round of implants. This priming of 
the tissues prior to implantation may have allowed a similar degree of cellular infiltrate, 
particularly neutrophils, to migrate through the collagen regardless of vaccination status. 
With acid-fast staining, a trend in bacterial load was not observed between the different 
experimental groups; however, presence of intracellular bacteria was observed in all 
implants. The detection of intracellular bacteria in the collagen implant demonstrated that the 
device’s ability to attract leukocytes for migration into the collagen and subsequent bacterial 
phagocytosis. 
Immunohistochemical staining with the macrophage-specific calcium-binding 
protein, Iba-1, was used to assess for macrophagic infiltrate in the collagen sections, and only 
rare Iba-1 positive cells were found in the collagen of vaccinated calves. However, histology 
of the tissues surrounding the implant revealed a marked inflammatory response with a large 
number of macrophages present. Acid-fast staining revealed the presence of bacteria in the 
surrounding tissues of some calves and the prescapular lymph node of one calf; quantity of 
acid-fast bacterial load appeared independent of vaccination status. The significance of the 
89 
 
 
 
 
rare macrophages within the implant from a vaccinated calf is unknown. One theory is that 
the degree of macrophagic inflammation outside the implant needed more time to migrate 
into the collagen, and repeat studies of extended duration may be beneficial. Although 
macrophages were only noted in one implant, a second theory is the ability of the vaccinated 
calf to attract macrophages into the collagen for bacterial engulfment; it is well-known that a 
previously primed Th1 cell infiltrates the site of exposure and recognizes peptide:MHC II 
complexes. This is followed by secretion of pro-inflammatory cytokines, such as IFN, 
leading to the activation and recruitment of more macrophages to the exposure site [41]. 
In conclusion, we adapted a previously designed subcutaneous implant device and 
explored its ability to function as a bacterial killing assay. Through fluorescently labeled 
bacteria and flow cytometric analysis, we were able to enumerate the dead bacteria in naïve 
and vaccinated calves. Three weeks post-vaccination, a significantly higher percentage of 
dead bacteria within the implant collagen was observed; this finding suggested that 
vaccinated calves can be evaluated for vaccine-induced killing responses and serve as a 
potential screening test; this screening test would facilitate selection of vaccine candidates for 
more extensive, Phase III, vaccine trials. A subcutaneous bacterial challenge model could 
prove to be an efficient and cost-effective method for screening novel vaccine candidates in a 
natural host model. 
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Figure 1: Flow cytometric analysis of bacterial viability 2 weeks post-vaccination. A-D 
Demonstrates the establishment of gates. A- Collagen and MAP. B - Collagen only. C – MAP 
only. D – Collagen and unstained MAP. E – Vaccinated calf.  F - Naïve calf. G – Bacteria 
from implants (n=9 per group) retrieved from vaccinated calves and naïve calves did not 
exhibit significant differences. Data are expressed as means +/- SEMs. SSC-A (side scatter 
area), FSC-A (forward scatter area), PI (propidium iodide), PE (phycoerythrin). 
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Figure 2: Flow cytometric analysis of bacterial viability 3 weeks post vaccination. A-D 
Demonstrates the establishment of gates. A- Collagen and MAP. B - Collagen only. C – MAP 
only. D – Collagen and unstained MAP. E – Vaccinated calf.  F - Naïve calf. G – Bacteria 
from implants (n=9 per group) retrieved from vaccinated calves contained a significantly 
greater percentage of PI+ (dead) bacteria. Data are expressed as means +/- SEMs. *P < 0.05. 
SSC-A (side scatter area), FSC-A (forward scatter area), PI (propidium iodide), PE 
(phycoerythrin). 
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Figure 3: IFNlevels from retrieved implant collagen at 3 weeks post vaccination. IFN levels 
from retrieved implant collagen 3 weeks post vaccination. Data are expressed as means +/- SEMs. 
*P < 0.005. 
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Figure 4: IFNlevels from stimulated peripheral blood leukocytes. A- 2 weeks, B – 3 
weeks. IFNlevels from medium alone (no stimulation) were subtracted from ConA and 
PPD-J. Statistical differences were not observed between ConA stimulation or PPD-J 
stimulation of vaccinated and naïve calves. ConA – ConcanavalinA, PPD-J - purified protein 
derivative-johnin. 
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Figure 5 & Table 1: Caudal tail-fold skin test thickness. Skin test thickness 
was measured once at the end of the project. Statistical differences were not 
observed between vaccinated and naïve cattle. 
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Figure 6: Histopathologic examination of implants. All figures are observed at 100x 
magnification with a 400x magnification inset. A,C,F – Vaccinated calf. B,D,G – Naïve calf. 
A,B – H&E sections. C, D – Ziehl-Neelsen acid fast stained. E,F,G- Iba-1 (macrophage- 
specific calcium-binding protein) stained. 
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
 
 
 
 
 
 
 
 
* 
 
 
 
 
 
 
* 
 
 
 
 
Figure 7: Histopathologic examination of tissue surrounding implant. A-C, H&E. D-E, 
Ziehl-Neelsen acid-fast. A, B, C- 20x, 100x, & 400x, tissue surrounding implant. The area 
where implant was removed is marked with red asterisks. D, E – Acid-fast stained tissue 
surrounding implant at 40x shows subcutaneous bacteria outside of implant. Low numbers of 
MAP were observed in the subcutaneous of some calves and appeared independent of 
vaccination status. 
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Figure 8: A, B – Histopathologic examination of prescapular lymph node. 400x, Ziehl- 
Neelsen acid-fast stained, prescapular lymph nodes. A- Lymph node without acid-fast 
bacteria. B- Red arrows show intracellular acid-fast bacteria within the prescapular lymph 
node. Low numbers of MAP were observed in the prescapular lymph nodes of some calves 
and appeared independent of vaccination status. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
 
 
Summary 
 
The central hypothesis of this dissertation was that a self-contained, collagen-containing 
implant device could be developed to detect vaccination-induced, cell-mediated immunity in the 
subcutaneous tissue of calves. The long-term, future aim of these combined studies is to use the 
implant device to efficiently screen novel MAP vaccine candidates. This in vivo screening test 
would rapidly and inexpensively provide knowledge of a vaccine’s efficacy in the host species; 
vaccine candidates exhibiting evidence of efficacy could then be selected for more extensive 
vaccine challenge studies. A better understanding of in vivo cell-mediated immunity in response 
to MAP immunization is essential for the development of a novel vaccine screening test. In all of 
the studies presented, Mycopar® vaccinated bull calves were compared to unvaccinated, control 
calves. 
In Chapter 2, our specific aim was based on a proof-of-concept study that focused on the 
development of a platform for in vivo detection of cell-mediated immunity in cattle. Our strategy 
was to design an easily removable device that can house MAP antigen and collect immune 
parameters while placed in the subcutaneous tissues. The principle for this design approach is 
that such a device will measure immune parameters at the site of antigen exposure in a living calf 
and represent a more accurate reflection of the true immune response observed in infection and 
vaccination. 
This first study was a small (n=4) pilot study and focused on the implant design, 
implantation procedure, collagen processing, and immune parameter retrieval. The design of the 
device and procedure for implantation is described thoroughly in Chapter 2. Histological sections 
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were examined along with the concentrations of cytokine from the retrieved collagen. The results 
of the study provided evidence that MAP-specific in vivo measurements can be achieved with the 
use of this implant device. Histological analysis revealed a lack of cellular infiltrate in naïve 
calves as well as the vaccinated calf not challenged with MAP antigen (PPD-J). This 
demonstrated antigen dependent immune cell recruitment into the implant. It showed the 
collagen’s capacity for cellular migration. We hypothesized an elevation in IFNand decrease 
level of IL-10 in the retrieved collagen. As expected, IFNwas only detected in the antigen- 
containing implants that were placed in vaccinated calves. IL-10 did not exhibit antigen or 
vaccine-dependent trends. Overall, the advantage of this novel device is the ability to measure 
multiple immune parameters upon collagen retrieval to more accurately assess the in vivo 
immune response. 
In Chapter 3, we built on our initial proof-of-concept investigation by evaluating the 
implant device’s ability to consistently and repeatedly measure immune parameters in a 
longitudinal study comparing naïve and vaccinated calves. Our hypothesis for these studies was 
that the implant device will detect vaccination-induced cell-mediated immunity in vaccinated 
calves that differs from the immunity observed in naïve calves. To test our hypothesis, an 8 week 
longitudinal investigation was conducted to evaluate the device’s success at identifying 
vaccinated calves from naïve calves. The implants contained either collagen with saline only or 
collagen with MAP antigen, and cytokine (IFNand IL-10) levels within the implant were 
measured at 0, 2, 4, 6, and 8 weeks post-vaccination. IFNlevels in the MAP antigen-containing 
implants placed in vaccinated calves were significantly higher than the implants retrieved from 
naïve cattle at weeks 4 and 6 post-vaccination. These responses paralleled the responses 
observed in MAP-stimulated PBL from vaccinated calves. Significant differences in IL-10 levels 
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between the implants within vaccinated and naïve calves were not observed. The intradermal 
caudal fold test (CFT) demonstrated false-positive rates when one of our calves reacted to PPD-J 
prior to vaccination. Therefore, our implant device was capable of identifying each of the 3 
vaccinated calves, suggesting an increased specificity over the intradermal CFT using PPD-J. 
Overall, the implant device consistently detected in vivo immune parameters and evidence 
showed this device may have a greater specificity than standard intradermal skin tests. 
Our final aim, investigated in Chapter 4, involved an adaptation of the previously 
designed implant device; in Chapters 1 and 2, the MAP antigen, PPD-J, was used in the collagen 
matrix. In contrast, our final project used live MAP bacteria and explored the device’s potential 
as a bacterial killing assay. The research in this chapter used the implant device as a platform for 
assessing bacterial viability in Mycopar® vaccinated calves. 
In this study, collagen and MAP-containing implant devices were placed in the 
subcutaneous tissues of calves divided into two groups, naïve and vaccinated calves, at 14 and 20 
days post-vaccination. After 5 days, implants were retrieved from the subcutaneous tissues and 
collagen was processed for evaluation of IFNcytokine levels and flow cytometric analysis of 
bacterial viability. Three weeks post-vaccination, flow cytometric analysis of the bacteria 
removed from collagen demonstrated a significantly greater percentage of propidium iodide (PI) 
stained-MAP in the vaccinated calves compared to naïve calves. This indicated an enhancement 
of bacterial killing within the group of vaccinated calves. Collagen from vaccinated calves at the 
three week time point also demonstrated a significantly higher production of IFN than collagen 
from naïve calves. 
Using flow cytometry to assess bacterial viability, this investigation demonstrated the 
device’s potential as a bacterial challenge model. A subcutaneous bacterial challenge model 
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could prove to be an efficient and cost effective method for screening novel vaccine candidates 
in a natural host model. 
 
 
Future Directions 
 
Various methods are currently recommended in the control of Johne’s disease in our 
cattle herds such as improvement of biosecurity methods and better test-and-cull management 
strategies [1, 2]. Although such strategies have been implemented, MAP infection continues to 
exist and cause substantial economic losses across the United States and worldwide [3-5]. 
Vaccination programs may contain the greatest potential for elimination of MAP infection in 
ruminants. One of the largest obstacles in the development of new vaccines is the poor 
correlation between initial screening tests and secondary evaluation methods in the sheep and 
cattle natural host models [6-8]. A better understanding of how the host immune system responds 
to local antigen exposure may substantially accelerate our progress in developing a vaccine 
candidate capable of mounting a fully protective immune response. 
In Chapter 2, we developed a removable subcutaneous device that housed MAP antigen 
while allowing migration of cell-mediated immune parameters into the collagen for collection 
and analysis. In this study, the MAP antigen chosen for placement in the collagen was PPD-J. In 
our research, a false-positive intradermal CFT was identified when one of our calves responded 
to the PPD-J prior to MAP vaccination. This is similar to results seen in other vaccination studies 
in which intradermal skin testing has been shown to have variable false-positive rates due to 
sensitization and cross-reactivity of environmental mycobacteria [9-12]. Future studies may 
benefit from inclusion of antigens specific to individual species of mycobacteria. Evaluating 
MAP candidate antigens for improved specificity and superior immune protection is an active 
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area of research in the field of mycobacteria [13-15]. It is possible with the use of one or more 
MAP-specific antigens that this implant device may be able to differentiate vaccinated calves 
from subclinical and clinically infected cattle. 
In Chapter 3, we conducted a longitudinal evaluation of in vivo immune responses 
collected from the collagen within our subcutaneous implant device. The cytokines included in 
this dissertation included IFNand IL-10. Levels of IFNwithin implants from calves vaccinated 
with Mycopar® were higher than those from naïve cattle beginning at week 2 post-vaccination. 
There were no significant differences between vaccinated and naïve calves in IL-10 levels within 
the implants at any time point in the study. 
Numerous studies investigating cytokine profiling in MAP infection has focused on 
peripheral blood immune responses, as well as sites of infection such as ileum and lymph node 
[16, 17]. There have been several papers focused on cytokine expression profiles in cattle, sheep, 
and goats [18-20]. One example is the extensive work by Coussens et al. and their examination 
of the gene expression of 13 different cytokines in PBMCs, intestinal lesions, and mesenteric 
lymph nodes of MAP-infected and naïve cattle. These findings provided evidence for the 
enhancement of anti-inflammatory cytokines and suppression of pro-inflammatory cytokines 
when cells were stimulated with MAP antigen. Minimal literature exists on the immune 
responses, cellular infiltrate, and cytokine profiles observed within the intradermal CFT site in 
cattle. However, some human studies have used immunohistochemical stains to evaluate 
cytokines at several time points post-PPD intradermal injection in BCG-vaccinated individuals 
[21]. Although the IFNlevels within the implants throughout this dissertation proved to be 
consistent and significantly different between experimental groups, assessing a larger number 
cytokines could provide a better understanding of the in vivo cytokine levels in MAP-induced 
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DTH reactions. A more extensive profile evaluating the expression of multiple cytokines at the 
DTH site may prove beneficial to future investigations utilizing this implant device. 
In Chapter 4, we adapted the implant device for use as a bacterial challenge model. Our 
results showed a significantly greater percentage of propidium iodide (PI) stained-MAP in the 
vaccinated calves compared to naïve calves, indicating enhanced bacterial killing within the 
vaccinated calves. The enhanced bacterial killing observed in the collagen from vaccinated 
calves also contained significantly greater concentrations of IFN. It is well known that IFNis 
produced by natural killer (NK) cells, NK- T cells, CD4 Th1, and CD8 cytotoxic T lymphocyte 
(CTL) effector T cells [22]; however, only low numbers of lymphocytes were observed in the 
histologic sections. Further research is necessary to identify the cells producing the elevated 
IFNobserved in vaccinated animals. It is plausible that the lymphocytes, albeit in low numbers, 
are producing high levels of IFNin vaccinated calves. Alternatively, some human studies have 
shown neutrophils are a source of IFNduring acute infections, and they should be ruled out as a 
source for the IFNproduction [23, 24]. Irrespective of their role in IFNproduction, neutrophils 
have been shown to play a protective role in M. tuberculosis infection in mice [25], and future 
studies are needed to further evaluate the role neutrophils may play in the immune response that 
has been repeatedly observed in the histologic sections of implant collagen.  
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